



## Review

# From old to new — Repurposing drugs to target mitochondrial energy metabolism in cancer

Sepideh Aminzadeh-Gohari<sup>a</sup>, Daniela D. Weber<sup>a</sup>, Silvia Vidali<sup>a,b</sup>, Luca Catalano<sup>a</sup>, Barbara Kofler<sup>a,\*</sup>, René G. Feichtinger<sup>a</sup>

<sup>a</sup> Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria

<sup>b</sup> Institute of Human Genetics, Helmholtz Zentrum München, Technical University of Munich, Munich, Germany

## ARTICLE INFO

## Keywords:

Aerobic mitochondrial energy metabolism  
Oxidative phosphorylation complex  
Antibiotic  
Antidiabetic  
Chemotherapeutic

## ABSTRACT

Although we have entered the era of personalized medicine and tailored therapies, drugs that target a large variety of cancers regardless of individual patient differences would be a major advance nonetheless. This review article summarizes current concepts and therapeutic opportunities in the area of targeting aerobic mitochondrial energy metabolism in cancer. Old drugs previously used for diseases other than cancer, such as antibiotics and antidiabetics, have the potential to inhibit the growth of various tumor entities. Many drugs are reported to influence mitochondrial metabolism. However, here we consider only those drugs which predominantly inhibit oxidative phosphorylation.

## 1. Introduction

Cancer is one of the most devastating and intractable diseases. For example, it is the second causing deaths in the United States [1]. During the last decade, substantial progress has been made in genetic diagnostics, especially in the area of exome and whole-genome sequencing [2]. Moreover, the development of RNA sequencing is enabling elucidation of the function of genetic variants whose pathogenic relevance has been unclear [3,4]. These technical advances have also led to significant cost reductions, thus providing the foundation for personalized / precision medicine in the treatment of cancer [5]. However, because of the enormous heterogeneity and numerous inter-individual genetic differences, new therapies usually target only very small patient cohorts. An emerging broad-spectrum approach to cancer therapy depends on the fact that many tumors are characterized by enhanced glycolysis and low but mostly functional oxidative phosphorylation (OXPHOS), a phenotype first described by the Nobel laureate Otto Warburg more than 80 years ago [6,7]. Therefore, metabolic therapies have the potential to be applied against a vast array of tumor entities.

There is increasing evidence that several drugs with potent anti-tumor activity act *via* targeting mitochondrial aerobic metabolism. Possible targets include the five OXPHOS complexes, mitochondrial translation, and mitochondrial biogenesis. Other parameters of mitochondrial function such as mitochondrial morphology may also be impacted by these drugs, but the experimental evidence is sparse and inconclusive in terms of therapeutic significance.

The Warburg effect describes the abnormality wherein cancer cells generate energy predominantly *via* glycolysis even if sufficient oxygen is present. It seems a paradox that tumors use inefficient glycolysis instead of OXPHOS for energy production, but there are several explanations for why the principal pathway of ATP generation is reprogrammed in cancer cells. Foremost, aerobic glycolysis is not as inefficient as is often assumed. Although it is correct that the amount of ATP generated per molecule of glucose is low, the rate of glucose metabolism is high in cancer cells. The production of lactate from glucose occurs 10–100 times faster than the complete oxidation of glucose in mitochondria, therefore ATP production is similar [8].

Many tumors are characterized by low OXPHOS. However, the

**Abbreviations:** AM, antimicrobial therapeutic; AML, acute myeloid leukemia; AMP, adenosine monophosphate; ATP, adenosine triphosphate; BACH1, BTB and CNC homology1; CAFs, Cancer-associated fibroblasts; CPT, cisplatin; CSC, cancer stem cell; DFP, Deferiprone; DOX, Doxorubicin; DNA, Deoxyribonucleic acid; FDA, Food and Drug Administration; mtDNA, mitochondrial deoxyribonucleic acid; NAD, nicotinamide adenine dinucleotide; NSAID, Non-steroidal anti-inflammatory drug; OXPHOS, oxidative phosphorylation; PCA, prostate cancer; PTEN, Phosphatase and tensin homolog; RNA, ribonucleic acid; ROS, reactive oxygen species; SFB, Sorafenib; TCA, tricarboxylic acid; TAM, Tamoxifen; TM, Tetrathiomolybdate; VDACL1, voltage-dependent anion-selective channel 1; 2DG, 2-deoxyglucose;  $\Delta$ 9-THC,  $\Delta$ 9-tetrahydrocannabinol;  $\Delta$ 8-THC,  $\Delta$ 8-tetrahydrocannabinol

\* Corresponding author at: Research Program for Receptor Biochemistry and Tumor Metabolism, University Hospital Salzburg, Paracelsus Medical University, Muellner-Hauptstrasse 48, 5020 Salzburg, Austria.

E-mail address: [b.kofler@salk.at](mailto:b.kofler@salk.at) (B. Kofler).


<https://doi.org/10.1016/j.semcdb.2019.05.025>

Received 29 March 2019; Received in revised form 23 May 2019; Accepted 23 May 2019

Available online 04 June 2019

1084-9521/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



**Fig. 1.** Targeting mitochondrial aerobic metabolism by FDA-approved agents for cancer treatment. Abbreviations: I, Complex I; II, Complex II; III, Complex III; IV, Complex IV; V, Complex V. OXPPOS, oxidative phosphorylation; mtDNA, mitochondrial DNA; Mitoribosome, mitochondrial ribosome; VDAC1, voltage-dependent anion-selective channel 1.

reasons for this pathology differ between cancer entities. Some tumors carry pathogenic mutations in mtDNA-encoded complex I subunits (e.g. renal oncocytomas) or nuclear-encoded complex II subunits (e.g. pheochromocytomas and paragangliomas); others show a reduction of all OXPPOS complexes, with a reduction of mtDNA copy number; and still others have low mitochondrial mass [9–13]. The genetic cause of this downregulation remains elusive in many cases. Many entities show a homogenous reduction of OXPPOS, such as oncogenic tumors, neuroblastomas, renal cell carcinomas and astrocytic brain tumors [10,11,14]. However, only a subset of carcinomas and melanomas is OXPPOS deficient, the others retaining a functional OXPPOS system [15–20]. The OXPPOS dependence of certain cancer subtypes is influenced either by genetic alterations and/or tumor microenvironment. For example, KRAS driven in lung cancer showed increased glucose contribution to the tricarboxylic acid (TCA) cycle relative to normal lung tissue [21]. Furthermore, alterations in components of the SWI/SNF chromatin complex including SMARCA4 are frequently detected in lung cancer. Tumors with SMARCA4 mutations are characterized by enhanced OXPPOS as well as respiratory capacity and are therefore sensitive to OXPPOS inhibition [22]. In contrast to Phosphatase and tensin homolog (PTEN) wild type prostate cancer cells, mitochondria of PTEN-null cells consume ATP through complex V, instead of producing it, which resulted in genotype specific sensitivity to complex I inhibition *in vitro* [23].

BTB and CNC homology1 (BACH1), a haem-binding transcription factor that is increased in expression in tumors from patients with triple negative breast cancer, decreases glucose utilization in the TCA cycle and downregulates expression of OXPPOS genes. Thus, BACH1 gene expression inversely correlates with OXPPOS gene expression in tumors from patients with breast cancer [24].

Moreover, cancer cells have the capacity to use a variety of substrates to fuel the mitochondrial respiration (fatty acids, glutamine,

lactate, acetate...) [25–28]. This has been demonstrated for example *in vivo* in human cancer patients and diverse animal models *via* infusion of <sup>13</sup>C-labelled substrates [25–27].

Cells exposed to acidosis largely rely upon mitochondrial metabolism for energy generation to the extent that metabolic intermediates are redirected away from several other critical metabolic processes, including ribose and glutathione synthesis [29]. The metabolic adaptation of cancer cells to chronic acidosis causes a shift from glucose to glutamine metabolism and glutamine fueled OXPPOS in different tumor cell lines [30]. Furthermore, lactate produced by enhanced glycolysis can also be used as a metabolic fuel by oxidative cancer cells [26,31,32] but also nearly all normal tissues [27].

In all these scenarios the tumor microenvironment has to be taken in consideration. The tumor microenvironment is characterized by different factors such as an increased level of lactate and/or CO<sub>2</sub>, produced by tumor cells. As shown in lung cancer, a hypercapnic tumor environment reduces mitochondrial respiration, leading to chemoresistance [178]. Cancer-associated fibroblasts (CAFs) are the major cellular stromal component of many solid tumors. For example in prostate cancer (PCa), CAFs establish a metabolic symbiosis with PCa cells, contributing to cancer aggressiveness through lactate shuttle. Cancer cells are even able to hijack CAF-derived functional mitochondria through the formation of cellular bridges [179].

In this article, we discuss the therapeutic potential of targeting mitochondrial energy metabolism and the mechanisms behind the various approaches.

Many FDA-approved drugs initially used for the treatment of non-cancer illnesses are now being repurposed for tumor therapy in light of increased knowledge about their mechanisms of action. Drugs with minimal side effects on whole-body metabolism exploit the Warburg effect in cancer cells. However, certain traditional chemotherapeutics may act by inhibiting aerobic mitochondrial energy metabolism. This

**Table 1**  
Effects of FDA-approved anti-microbial agents on mitochondrial aerobic metabolism of cancer cells in *in vitro*, preclinical and clinical studies.

Type of cancer	Type of study	Effects on mitochondrial aerobic metabolism	Effects on cancer progression	Ref
<b>Atovaquone</b>				
Breast	<i>In vitro</i>	↓ Complex III, ↓ respiration, ↓ ATP production, ↓ MIT mass	↓ CG & CSCs	[62]
Squamous cell carcinoma, colon, lung & pharynx	<i>In vitro/in vivo</i> +/- radiation treatment	↓ Complex III, ↓ respiration	↓ CG & TG, ↑ sensitization to radiation	[66]
<b>Bedaquiline</b>				
Breast	<i>In vitro</i>	↓ Respiration, ↓ ATP production	↓ CSC propagation & survival, a little or no effect on viability of cancer / normal cells	[54]
Lung	<i>In vitro/in vivo</i>	↓ Respiration, ↓ ATP production	↓ CG & TG, ↑ apoptosis	[55]
<b>Chloramphenicol</b>				
Multiple myeloma	<i>In vitro</i>	↓ ATP production	↓ CG, ↑ apoptosis	[56]
<b>Doxycycline</b>				
Breast	<i>In vitro</i> +/- chemotherapy	↓ MIT biogenesis	↓ hypoxic CSCs, ↑ sensitization to chemotherapy	[74]
Breast	<i>In vitro</i> +/- radiation treatment	↓ Protein synthesis, ↓ respiration & ATP production	↑ sensitization CSCs to radiation	[36]
Breast	Clinical	No change in level of MIT marker	↓ Stemness markers, no difference in level of proliferation	[72]
Cervical	<i>In vitro/in vivo</i>	↓ Respiration, ↓ ATP production	↓ CG & TG, ↑ apoptosis	[35]
Glioblastoma	<i>In vitro / in vivo</i> +/- chemotherapy	↓ Respiration, ↓ ATP production	↓ CG & TG, ↑ sensitization to chemotherapy	[58]
Glioma	<i>In vitro</i>	↓ Protein synthesis, ↓ respiration	↓ CG	[65]
<b>Itraconazole</b>				
Glioblastoma	<i>In vitro/in vivo</i>	Interaction with VDAC1	↓ CG & TG	[70]
<b>Ivermectin</b>				
Chronic myeloid leukemia	<i>In vitro / in vivo</i>	↓ Complex I activity, ↓ respiration	↓ CG & TG, ↑ apoptosis	[42]
Glioblastoma	<i>In vitro/in vivo</i>	↓ Complex I, ↓ respiration, ↓ ATP production	↓ CG & TG, ↑ apoptosis	[44]
Renal	<i>In vitro/in vivo</i>	↓ Respiration, ↓ ATP production	↓ CG & TG, ↑ apoptosis	[64]
<b>Pyrvinium pamoate</b>				
Breast, pancreatic, colon & cervical cancer	<i>In vitro/in vivo</i> +/- glycolysis inhibitor	↓ ATP production	↓ CG & TG, ↑ apoptosis	[39]
Lymphoma	<i>In vitro</i>	↓ Complex I, ↓ respiration, ↓ ATP production	↑ Apoptosis	[47]
Phase-chronic myeloid leukemia	<i>In vitro / in vivo</i> +/- targeted therapy	↓ Respiration, ↓ ATP production	↓ CG & TG, ↑ effect of targeted therapy	[45]
Myeloma / erythroleukemia	<i>In vitro</i>	↓ Complex I, ↓ respiration, ↓ ATP production	↓ CG	[67]
<b>Tetracycline analogues (doxycycline &amp; COL-3)</b>				
Adenocarcinomas of alveolar, pancreatic & colon	<i>In vitro</i>	↓ MIT protein synthesis, ↓ complex IV activity	↓ CG, higher cytotoxicity of COL-3 compared to doxycycline	[59]
<b>Tigecycline</b>				
Acute lymphoblastic leukemia	<i>In vitro / in vivo</i> +/- chemotherapy	↓ Respiration, ↓ ATP production	↓ CG & TG, ↑ apoptosis, ↑ sensitization to chemotherapy	[52]
Acute myeloid leukemia	<i>In vitro/in vivo</i>	↓ MIT protein synthesis, ↓ respiration, ↓ complex I & IV activity	↓ CG & TG, targeting leukemia stem cells	[60]
Acute myeloid leukemia	<i>In vitro / in vivo</i> +/- chemotherapy	↓ MIT mass, ↓ respiration	↓ CG & TG, ↑ apoptosis, ↑ sensitization to chemotherapy	[50]
Chronic myeloid leukemia	<i>In vitro</i>	↓ MIT protein synthesis, ↓ respiration	↓ CG, ↑ apoptosis, overcoming drug resistance	[38]
Chronic myeloid leukemia	<i>In vitro/in vivo</i> +/- targeted therapy	↓ MIT protein synthesis, ↓ respiration	↓ CG, ↓ TG in combination with protein kinase inhibitor	[51]

(continued on next page)

Table 1 (continued)

Type of cancer	Type of study	Effects on mitochondrial aerobic metabolism	Effects on cancer progression	Ref
OXPHOS-Large B-cell lymphoma Lung	<i>In vitro</i>	↓ Complex I, ↓ respiration	↓ CG	[49]
	<i>In vitro/in vivo</i>	↓ Respiration, ↓ ATP production	↓ CG & TG, ↑ apoptosis	[61]
Ovarian	<i>In vitro / in vivo</i> +/- chemotherapy	↓ MIT protein synthesis, ↓respiration	↓ CG & TG, ↑ sensitization to chemotherapy	[43]
Retinoblastoma	<i>In vitro/in vivo</i>	↓ MIT protein synthesis, ↓ respiration, ↓ activities of complex I & IV, ↓ ATP production	↓ CG & TG, ↑ apoptosis	[46]
Renal cell carcinoma	<i>In vitro/in vivo</i> +/- chemotherapy	↓ MIT protein synthesis, ↓ activities of complex I, IV & V	↓ CG & TG, ↑ sensitization to chemotherapy	[41]

Abbreviations: CG, Cell growth; CSC, Cancer stem cell; MIT, mitochondrial; TG, Tumor growth; VDACL1, voltage-dependent anion-selective channel 1. Signs: &, and; ↓, Decrease; ↑, Increase; +, In combination with; -, Without.

review focuses on very concrete changes of mitochondrial energy function. Only FDA-approved drugs that affect specific mitochondrial components or functions - OXPHOS complexes; oxygen consumption; enzymatic activity; mitochondrial replication, transcription or translation; mitochondrial fission and fusion; or mitochondrial biogenesis - are considered for their ability to target tumor metabolism (Fig. 1).

## 2. Antimicrobial agents

Growing clinical and pre-clinical evidence indicates that many commonly used antimicrobial (AM) therapeutics such as antibiotics, antiparasitics and antifungal drugs have anticancer effects against a wide spectrum of solid tumors and blood cancers (e.g. breast, brain, cervix, lung, kidney, ovary, retinoblastoma, multiple myeloma and leukemia). As shown in various studies, the underlying anticancer mechanisms of AMs are linked to their effects on key proteins involved in glycolysis, the response to DNA damage, protein degradation, angiogenesis, autophagy, the cell cycle and different signaling pathways [33–39]. However, a particularly important aspect of the anticancer effects of AM therapy is the interference with mitochondrial function [38,40–51] (Table 1). The endosymbiotic hypothesis proposes that mitochondria originated from bacteria; consequently, several antibiotics target these cellular organelles, too. AMs alter mitochondrial function by reducing mitochondrial biogenesis, altering mitochondrial morphology, lowering ATP production and increasing the level of reactive oxygen species (ROS), ultimately resulting in energy stress and anti-proliferative and pro-apoptotic effects. *In vitro* studies showed that cancer cells depleted of mitochondrial DNA ( $\rho 0$ ) are resistant to AMs in terms of suppression of cell proliferation or induction of apoptosis, emphasizing that AMs specifically target mitochondria [41,43–47,52]. In fact, AMs can cause mitochondrial dysfunction in both normal [53] and cancer cells [36,38,40,41,43,44,46,48,49,54–62], although rapidly dividing malignant cells with high energy demands are more sensitive to AMs [38,42,43,54,56,58–61,63,64] (Table 1).

Examples of AMs that suppress cancer by altering mitochondrial aerobic metabolism are provided below in more detail. Members of the Tetracycline and Chloramphenicol family of commonly used antibiotics inhibit both mitochondrial and bacterial translation [36,38,41,43,46,49,50,57–59,65]. Consistent with inhibition of mitochondrial translation, these antibiotics reduce the activities of OXPHOS complexes I, IV and V, which contain mitochondrially encoded subunits [41,46,59,60]. The antibiotic Bedaquiline, originally developed to eradicate aerobic bacteria, targets mitochondrial and bacterial ATP synthase [54,55]. Atovaquone, an antimalarial drug, is an inhibitor of OXPHOS complex III [62,66]. Ivermectin, a treatment for many types of parasites, inhibits complex I activity [42,44]. Pyrvinium pamoate, an anti-pinworm and anti-malarial medication, inhibits the mitochondrial NADH-fumarate reductase system, which is composed of complex I and II [39,45,67,68]. Itraconazole, a broad-spectrum anti-fungal agent,

binds to mitochondrial protein voltage-dependent anion-selective channel 1 (VDACL1) and reduces the level of ATP production [69,70]. Additionally, other classes of antimicrobial agents such as quinolones, aminoglycosides,  $\beta$ -lactams and oxazolidinones also cause mitochondrial dysfunction in mammalian cells [53,71], although their effects on aerobic metabolism in cancer cells are barely investigated.

Remarkably, pre-clinical and clinical studies revealed that AMs such as Doxycycline, Tigecycline, Azithromycin, Chloramphenicol, Atovaquone and Bedaquiline can effectively target cancer stem cells (CSCs) of different types of cancers [36,54,57,72–74] (Table 1). For example in CML, Tigecycline targets the more oxidative, long-term leukemic stem cells that are hardly sensitive to Imatinib, a protein kinase inhibitor used in CML therapy, which targets more mature progenitors [51]. CSCs are associated with cancer initiation, progression, metastasis, tumor recurrence and drug resistance. Interestingly, CSCs have a high level of reliance on mitochondrial function [73–77]. For example, breast cancer-derived CSCs express an abundance of mitochondrial proteins involved in beta-oxidation, ketone body metabolism, mitochondrial biogenesis, the stress response to hypoxia, and inhibition of autophagy/mitophagy [74,77]. Interestingly, Farge et al. reported that an OXPHOS-dependent energetic flexibility may be more responsible for chemoresistance rather than cellular quiescence or stage of maturity of CSCs. Based on *in vitro* and *in vivo* findings, chemoresistant AML cells showed high OXPHOS status compared to AML chemosensitive cells. In this context, Tigecycline sensitized high OXPHOS AML cells to the chemotherapy [50].

In conclusion, AMs are promising as part of a multimodal treatment regimen to improve the efficacy of classic anticancer therapies and to overcome CSC-based drug resistance. Combinations of AMs can sensitize cancer cells and CSCs to classic chemo or radiation therapies [36,41,43,58,66,74]. Although most data support the potent anticancer mechanisms of AMs, caution is required. Some clinical studies have shown associations between certain AMs and increased cancer risk, likely due to altered organ microbiota, attenuated immune surveillance and increased inflammation [79–82].

## 3. Antidiabetic drugs

Metformin (*N,N*-dimethylbiguanide) is an inexpensive generic drug and one of the most commonly used therapies for type 2 diabetes. Indeed, it accounts for around 120 million prescriptions per year worldwide. Its long track record of tolerability and known pharmacokinetics assure an excellent safety profile [83].

The antidiabetic effect of Metformin derives from its capacity to lower the blood glucose concentration by (i) inhibiting hepatic gluconeogenesis [84], (ii) improving insulin sensitivity in muscle and (iii) lowering the free fatty acid concentration in plasma [85].

A retrospective study suggests Metformin may reduce cancer mortality [86]. Different metabolic pathways are involved in the

**Table 2**  
Effects of FDA-approved anti-diabetic agents on mitochondrial aerobic metabolism of cancer cells in *in vitro*, preclinical and clinical studies.

Type of cancer	Type of study	Effects on mitochondrial aerobic metabolism	Effects on cancer progression	Ref
<b>Canagliflozin</b>				
Prostate & lung	<i>In vitro/in vivo</i> +/- radiation & chemotherapy	↓ Complex I activity, ↓ ATP production	↓ CG	[109]
<b>Metformin</b>				
Breast	<i>In vitro</i>	↓ Complex I activity, ↓ respiration	↓ CG	[92]
Breast, gastric & osteosarcoma	<i>In vitro/in vivo</i> +/- glycolysis inhibitor	↓ ATP, ↓ expression of components of complex I	↑ Cell death, ↓ TG in combination with glycolysis inhibitor	[101]
Breast	Clinical	↑ OXPHOS relevant gene transcription in a subset of patients	Resistant to metformin treatment in subset of patients with OXPHOS transcriptional response	[102]
Colon	<i>In vitro/in vivo</i>	↓ Complex I activity, ↓ respiration	↓ CG & TG	[93]
Leukemic cells	<i>In vitro/in vivo</i>	↓ Complex I activity, ↓ respiration, ↓ ATP production	↓ CG & TG, ↑ apoptosis	[94]
Lung, Colon	<i>In vitro</i>	↓ ATP production, ↓ respiration	↓ CG	[98]
Ovarian	<i>In vitro/in vivo</i> /clinical	Alteration in MIT metabolism in patient and mouse ovarian tumors, ↓ ATP	↓ Cell viability, ↓ TG	[100]
Ovarian	<i>In vitro</i>	↓ Respiration	↓ CG	[97]
Prostate	<i>In vitro</i> +/- glycolysis inhibitor	↓ Complex I activity	↑ Apoptosis & arrest of cell cycle	[95]
Prostate	<i>In vitro/in vivo</i>	↓ Respiration	↓ CG	[91]
Thyroid	<i>In vitro/in vivo</i>	↓ Respiration	↓ TG	[96]
Breast, cervical, lung, bone	<i>In vitro/in vivo</i>	↓ Complex I activity, ↓ respiration	↓ CG, ↓ TG	[99]
<b>Pioglitazone</b>				
Prostate	<i>In vitro</i> +/- glycolysis inhibitor	↓ Respiration	↓ CG, ↑ efficacy + glycolysis inhibitor on spheroid model	[110]

Abbreviations: CG, Cell growth; MIT, mitochondrial; TG, Tumor growth. Signs: &, and; ↓, Decrease; ↑, Increase; +, In combination with; -, Without.

antitumorigenic effects of Metformin. Metformin leads to activation of AMP-activated protein kinase and inhibition of mammalian target of rapamycin, which results in inhibition of cell proliferation [87]. Moreover, Metformin lowers the blood concentration of insulin and insulin-like growth factor 1; the latter factor is often involved in tumor progression [87,88].

Another promising feature of Metformin is its capacity to target OXPHOS [89]. Evidence suggests Metformin may exert its anti-diabetic effects by targeting complex I of the mitochondrial respiratory chain [90]. Indeed, new studies show that Metformin inhibits the activity of complex I in a wide range of cancers [91–95] (Table 2). Moreover, Metformin reduces the oxygen consumption in different cancer models [91–94,96–99] (Table 2), likely through complex I inhibition. Similarly, ATP production is reduced by Metformin in a broad range of cancers [94,98,100,101]. In other cases, changes in the expression levels of complex I transcripts [102,103], and a lower NADH/NAD ratio were reported [99]. Recent findings suggest that the antiproliferative effect of Metformin is determined by the metabolic environment of the tumor, which can dramatically alter the sensitivity to Metformin [99]. Overall, the most common effects of Metformin on cancer progression are reduced tumor growth and higher apoptotic rate (Table 2).

Other biguanides have also shown anticancer effects. For example, Phenformin is considerably more potent than Metformin in abrogating the electron transport chain in leukemia cells [104]. However, Phenformin has been withdrawn from clinical use because it can cause severe lactic acidosis, and several fatal cases have been reported [105]. For this reason, studies of its anticancer effects have waned. In colorectal cancer, Phenformin inhibits complex I and oxygen consumption, and increases cancer cell radiosensitivity [106]. Phenformin has also been shown to reduce tumor growth in cancer models characterized by OXPHOS deficiency [107]. Moreover, Phenformin and Oxamate, an

inhibitor of lactate dehydrogenase, synergistically decrease respiration and ATP production. Likewise, cell and tumor growth are inhibited by this drug combination [108].

Canagliflozin, another antidiabetic drug, inhibits complex I and cell growth in prostate and lung cancer and it has a synergetic effect with radio- and chemo-therapy [109].

Pioglitazone, also targets mitochondria, inhibits oxygen consumption and shows an anti-proliferative effect in combination with the glycolysis inhibitor 2-deoxyglucose (2DG) [110].

In summary, antidiabetic drugs suppress tumor growth in a broad range of cancer models by targeting mitochondrial complex I (Table 2). For this reason, these drugs could potentially play a primary role in a multi-target metabolic treatment strategy to increase the efficacy of standard therapies or reduce their side effects through a low-dose regimen approach.

#### 4. Classic antitumor agents

Mitochondria can promote or negate the anticancer effects of many commonly used chemotherapeutic drugs. For example, they are essential for exploiting the pro-apoptotic effects of certain drugs, but they are sometimes responsible for the development of drug resistance. In this part of the review, we focus on antitumor agents that specifically target mitochondrial OXPHOS or biogenesis (Table 3).

For decades cisplatin (CPT) has been widely used for the treatment of different types of cancer. In isolated rat mitochondria, CPT induced increased state 2 and 4 respiration [111]. In different gastrointestinal cancers, CPT interferes with mitochondrial bioenergetics by increasing the permeability of the inner mitochondrial membrane, promoting mitochondrial uncoupling, and decreasing OXPHOS function [112]. Along these same lines, rats treated with a single dose of CPT showed a



**Table 3**  
Effects of FDA-approved antitumor agents on mitochondrial aerobic metabolism of cancer cells in *in vitro* and preclinical studies.

Type of cancer	Type of study	Effects on mitochondrial aerobic metabolism	Effects on cancer progression	Ref
Cisplatin				
Gastrointestinal cancer	<i>In vitro</i>	OXPPOS uncoupling, ↑ state 2, 3 & 4 respiration	↑ Apoptosis	[112]
Doxorubicin				
Colon	<i>In vitro</i>	Modulation OXPPOS genes	↑ Apoptosis	[119]
Sorafenib				
Neuroblastoma	<i>In vitro</i>	Destabilization of complex I, ↓ respiration	↑ Apoptosis	[121]
Tamoxifen				
Breast	<i>In vitro/in vivo</i> mitochondrially targeting tamoxifen	↓ Complex I	↓ TG, ↑ general cell death	[128]

Abbreviations: TG, Tumor growth. Signs: &, and; ↓, Decrease; ↑, Increase.

reduction of state 3 respiration and inhibition of complex I and ATP synthase activity [113].

Doxorubicin (DOX) is one of the most effective and widely used anticancer drugs. Its efficacy could be even higher, but the clinical dosage is limited due to the development of delayed, cumulative and dosage-dependent cardiotoxicity [114,115]. DOX has high affinity for cardiolipin, an inner mitochondrial membrane phospholipid, resulting in an elevated concentration of the drug in mitochondria [116]. Moreover, DOX intercalates into mtDNA, causing disruption of genes coding for subunits of OXPPOS complexes [117]. The main cause of the DOX-associated cardiotoxicity is the overproduction of ROS by cardiac mitochondria, coupled with mitochondrial membrane depolarization and mitochondrial dysfunction. In general, treatment with DOX has been associated with decreased expression of some OXPPOS proteins, or with OXPPOS defects, and increased mitochondrial-mediated apoptosis [114,118]. Interestingly, a recent *in vitro* study showed that preconditioning of cardiomyoblasts with a single nanomolar exposure to DOX induced a beneficial mitochondrial adaptation. The preconditioned cells were less susceptible to DOX toxicity when treated with a second, higher dose of DOX, compared to non-pretreated cells. Nine days after the nanomolar DOX administration, cells showed increased expression of some OXPPOS subunits, but not increased mitochondrial biogenesis [115].

In colon cancer cells treated with DOX, the expression profile of genes involved in mitochondrial energy metabolism was significantly changed. Interestingly, DOX effects were abrogated by complex I deficiency, but not complex II, suggesting that DOX binds to complex I to initiate the apoptotic process [119].

The multi-kinase inhibitor Sorafenib (SFB) is also able to inhibit mitochondrial respiration [120,121]. In neuroblastoma cells, SFB induced loss of mitochondrial transmembrane potential and destabilization of complex I [121]. SFB administered to four children with relapsed and refractory neuroblastoma showed antitumor effects in all four cases, without major adverse effects, although after a short stabilization time, tumor progression was again observed [122]. Addition of the glycolytic inhibitor 2-DG strongly increased the cytotoxicity of SFB in rat hepatocarcinoma and mouse melanoma cell lines, compared to cells treated with vehicle or SFB alone [120].

Tamoxifen (TAM) is a nonsteroidal anti-estrogenic compound that is widely used in the treatment of estrogen-dependent cancers, including estrogen receptor-positive breast cancer [123]. In breast cancer cells, TAM induced cytochrome c release from mitochondria, reduced the mitochondrial membrane potential and OXPPOS activity, and increased cell death [123]. In isolated rat liver mitochondria, TAM reduced OXPPOS activity and interfered with mitochondrial membrane polarization/depolarization fluctuations in a dose-dependent manner

[124]. Moreover, TAM significantly inhibited complex I activity by targeting the flavin mononucleotide site of complex I [125]. In addition, TAM significantly inhibited DNA topoisomerase and mtDNA synthesis, leading to progressive depletion of mtDNA in the liver of mice treated for more than 12 days [126]. Interestingly, TAM-resistant breast cancer cells show a “dormant” profile, with high mtDNA depletion and a very low respiration, compared to TAM-sensitive breast cancer cells [127].

Recently, TAM has been conjugated with a tag that selectively delivers it to mitochondria (MitoTam). MitoTam has been proven to inhibit complex I and to be more effective in reducing the growth of breast cancer xenografts *in vivo* compared to TAM, especially of xenografts expressing high levels of human epidermal growth factor receptor 2, an oncogene associated with development of resistance and poor prognosis, and implicated in upregulation of complex I activity in breast cancer [128]. MitoTam kills cancer cells without inducing senescence, and increases the amount of cell death of senescent cells, compared to other chemotherapeutics. Usually, senescent cells, including senescent cancer cells, are able to escape the immune system; thus, MitoTam is a promising new molecule for the treatment of breast cancer, and it is currently entering a phase I clinical trial [129].

## 5. Other FDA-approved agents and some novel compounds

This section focuses on compounds which do not belong to the categories discussed above and which could be repurposed for cancer therapy based on their anti-mitochondrial effects. In addition, several novel compounds targeting mitochondrial bioenergetics are discussed.

Cancer growth and proliferation rely on intracellular iron availability, thus iron has been suggested as an anticancer target. Iron is also essential for mitochondria, which utilize this metal for synthesis of cofactors involved in the function of oxidation-reduction enzymes, and for DNA synthesis and repair [130,131].

Deferiprone (DFP) is an orally administered iron chelator used clinically for the treatment of thalassemia, Friedreich's ataxia and kidney disease. DFP is also able to reduce the proliferation and migration of metastatic and non-metastatic prostate cancer cells. Moreover, DFP lowered the respiration rate as well as the expression and activity of mitochondrial aconitase in these cells [131] (Table 4).

VLX600, a recently designed iron chelator, interferes with intracellular iron metabolism. Iron chelation leads to inhibition of mitochondrial respiration, bioenergetic failure and cell death. VLX600 enhances the glycolytic pathway and decreases respiration and oxygen consumption [48,132,133]. Inhibition of mitochondrial respiration with VLX600 reduced human colon carcinoma cell growth *in vitro*, and mouse colon tumor xenograft growth *in vivo*, both in cells with or

**Table 4**Effects of further FDA-approved agents and some novel compounds on mitochondrial aerobic metabolism of cancer cells *in vitro* and preclinical studies.

Type of cancer	Type of study	Effects on mitochondrial aerobic metabolism	Effects on cancer progression	Ref
Antiepileptic drugs				
Valproate				
Liver	<i>In vitro</i>	↓ Respiration, ↓ ATP production	↓ CG	[156]
Cannabinoids				
Δ9 -tetrahydrocannabinol and Δ8 -tetrahydrocannabinol				
Oral squamous cell carcinoma	<i>In vitro</i>	↓ Respiration, ↓ ATP production	↑ Apoptosis	[154]
Chelating agents				
Deferiprone				
Prostate cancer	<i>In vitro</i>	↓ Respiration, ↓ ATP production	↓ CG & cell migrations	[131]
Tetrathiomolybdate				
Endometrial adenocarcinoma	<i>In vitro</i> +/- glycolysis inhibitor	↓ Complex IV activity, ↓ respiration	No effect on CG without combination with glycolysis inhibitor	[136]
Neuroblastoma	<i>In vitro</i> +/- Akt kinase inhibitor	↓ Respiration, ↓ ATP production	↓ CG	[139]
VLX600				
Colon carcinoma	<i>In vitro/in vivo</i> (+/-K-Ras mutation)	↓ Respiration	↓ CG & TG in combination with tigecycline	[48]
Colon carcinoma	<i>In vitro/ex vivo/in vivo</i>	↓ Respiration, ↓ complex I, II & IV activities	↓ CG, ↓ TG	[132]
Colon carcinoma & breast cancer	<i>In vitro</i>	↓ Respiration, ↓ complex IV activity	↓ CG	[133]
Gastrointestinal stromal tumor Non-steroidal anti-inflammatory drugs (NSAIDs)	<i>In vivo</i> ± Imatinib	↓ Respiration	↓CG & TG, ↑ apoptosis	[134]
Aspirin				
Liver	<i>In vitro</i>	↓ Complex I & IV activities, ↓ ATP production	↓ CG	[147]
Diclofenac				
Melanoma	<i>In vitro</i> +/- vemurafenib	↓ Respiration	↓ CG	[148]
Indomethacin				
Colorectal adenocarcinoma	<i>In vitro</i>	↓ Complex I activity, ↓ ATP production	↓ CG	[146]
Novel compounds				
BAY 87-2243				
Melanoma	<i>In vitro/in vivo</i>	↓ Complex I activity, ↓ ATP production	↓ CG, ↓ TG	[160]
IACS-010759				
Acute myeloid leukemia, low glycolytic glioblastoma & neuroblastoma	<i>In vitro/in vivo</i>	↓ Complex I activity, ↓ ATP production	↓ CG, ↓ TG, ↑ survival	[158]
Brain metastasis of MAPK inhibitor-resistant intracranial melanoma	<i>In vivo</i>		↑ Survival; ↓ brain metastasis	[159]
Gboxin				
Glioblastoma	<i>In vitro/in vivo</i>	↓ Respiration, ↓ complex V activity	↓ CG, ↓ TG, ↑ survival	[161]

Abbreviations: CG, Cell growth; TG, Tumor growth. Signs: &amp;, and; ↓, Decrease; ↑, Increase; +, In combination with; -, Without.

without K-Ras mutation [48]. Moreover, VLX600 has been reported to inhibit the growth of breast cancer and colon carcinoma cells, both in 3D spheroids and in 2D monolayers, and to be more potent than other iron chelators [132,133] (Table 4). VLX600 was tested *in vivo* with other compounds that are routinely used for clinical management of colon carcinoma patients. Synergy was observed with irinotecan and oxaliplatin, whereas additive effects were shown in combination with 5-fluorouracil [132]. In gastrointestinal stromal tumors, VLX600 increased the antitumor effect of Imatinib [134]. A phase I clinical trial performed on different types of advanced refractory carcinomas showed that VLX600 is generally well tolerated [135].

Another metal with important functions in cancer cell proliferation and invasion is copper. Tetrathiomolybdate (TM) is a copper-chelating drug currently used in the treatment of copper overload disorder. TM has also shown antitumor effects by reducing both angiogenesis and mitochondrial ATP production. TM reduces mitochondrial respiration *via* inhibition of the copper-dependent mitochondrial activity of complex IV and degradation of Hypoxia-inducible factor 1 $\alpha$  [136,137]. Prolonged copper depletion (by another copper chelator, triethylene tetramine) caused mitochondrial damage, oxidative stress and apoptosis in neuroblastoma cells *in vitro* [138]. Similarly, neuroblastoma cells treated with TM showed reduced mitochondrial respiration and cell proliferation [139]. Moreover, TM showed high specificity, selectively inhibiting neuroblastoma cell growth, and not the growth of normal fibroblasts and neuronal cells [139] (Table 4).

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed drugs worldwide (e.g. Aspirin, Ibuprofen, and Diclofenac). It is widely accepted that Aspirin, in particular, reduces the risk of developing cancer [140]. Besides the anti-inflammatory properties of NSAIDs, based on their inhibition of prostaglandin-synthesizing cyclooxygenase 1 and 2 [141], these compounds are considered to possess antitumor activity by inducing apoptosis *via* mitochondrial dysfunction and ROS production [142–144]. However, only a few studies have looked in detail into the effects NSAIDs may have on mitochondrial respiration in cancer models. The results indicate that a reduction of mitochondrial bioenergetics triggering oxidative stress seems to be the underlying molecular mechanism contributing to the reduced cell proliferation and thus apoptosis caused by NSAIDs. For example, Diclofenac produced strong inhibition of complex I in colorectal adenocarcinoma cells, followed by Piroxicam, Aspirin, Indomethacin, and Ibuprofen [145]. More specifically, complex I inhibition due to Aspirin and Indomethacin has been linked to reduced ATP production and cell proliferation in liver cancer and colorectal adenocarcinoma, respectively [146,147]. Moreover, in BRAF V600E mutated melanoma cells Diclofenac reduced proliferation partly due to inhibition of respiration [148]. However, the potency of those NSAIDs to reduce complex I activity is positively correlated with gastrointestinal side effects, except in the case of Diclofenac, which is relatively safe in terms of gastrointestinal toxicity but very potent in inhibiting complex I [145]. Besides inhibiting complex I, Aspirin also affects complex IV activity, leading to reduced ATP production and consequently reduced cell proliferation of human hepatoma cells [147] (Table 4).

Cannabinoids are another group of compounds which have gained interest for their use in cancer treatment and which are currently used to relieve cancer-associated pain and chemotherapy-induced nausea and vomiting [149]. Besides their palliative effects, phytocannabinoids, synthetic cannabinoids, and enhancers of endogenous cannabinoids have all been reported to possess antitumor activity. The major anticancerogenic effects shown *in vitro* and *in vivo* include reduction of proliferation, induction of apoptosis and autophagy, inhibition of invasion and angiogenesis, enhancement of tumor immune surveillance, and improved chemosensitivity to anticancer drugs [149,150]. Regarding the induction of apoptosis, cannabinoids have been reported to induce mitochondrial damage and increase ROS production [151–153]. However, as in the case of NSAIDs, less is known about the direct effects of cannabinoids on mitochondrial respiration and bioenergetics in

cancer cells. Whyte et al. investigated the effect of  $\Delta$ 9-tetrahydrocannabinol ( $\Delta$ 9-THC) and  $\Delta$ 8-tetrahydrocannabinol ( $\Delta$ 8-THC) on mitochondrial respiration in an *in vitro* model of human oral squamous cell carcinoma with high resistance to chemotherapeutic drugs [154]. The respiration of Tu183 cells decreased dose-dependently after  $\Delta$ 9-THC and  $\Delta$ 8-THC treatment, with the former being more efficacious in inhibiting oxygen consumption. As a consequence of reduced respiration,  $\Delta$ 9-THC decreased cellular ATP levels by 64% compared to control cells (Table 4). A possible mechanism by which  $\Delta$ 9-THC interferes with mitochondrial respiration could be its potential to interfere with mitochondrial respiratory chain complexes, as shown in mitochondria isolated from rat heart and liver [151,152]. However, caution is needed with respect to  $\Delta$ 9-THC. Even though cannabinoids have a favorable drug safety profile, the current clinical use of  $\Delta$ 9-THC is limited to its psychoactivity [149]. Thus, nonpsychoactive cannabinoids, such as cannabidiol, could represent an alternative to  $\Delta$ 9-THC.

Anti-epileptic drugs as well as antidepressants are known to cause mitochondrial toxicity and thus can be contraindicated in patients with mitochondrial diseases [155]. Regarding cancer, however, the mitochondrial toxicity of those drugs could selectively kill cancer cells at certain concentrations. For instance, the anti-epileptic drug Valproate reduced respiration and led to dysfunctional mitochondrial ATP production in hepatocellular carcinoma cells accompanied by increased cell death [156]. The tricyclic antidepressants Clomipramine, Norclomipramine, Amitriptyline and Doxepin significantly reduced cellular respiration of astrocytoma cells [157] (Table 4).

Besides well-characterized and often prescribed drugs, like the ones described so far, two novel compounds, IACS-010759 and BAY 87-2243, have been claimed to be antitumor agents based on their ability to selectively inhibit complex I activity *in vitro* and *in vivo*. The former has been studied in preclinical models of OXPHOS-dependent acute myeloid leukemia (AML), low-glycolytic glioblastoma and neuroblastoma as well as OXPHOS enriched melanoma brain metastasis [158,159]. IACS-010759 robustly inhibited cell viability and induced apoptosis, most likely due to OXPHOS inhibition leading to energy depletion and reduced nucleotide biosynthesis. *In vivo*, treatment of AML and brain cancer with IACS-010759 resulted in potent inhibition of tumor growth at well-tolerated doses (Table 4). Based on these findings, the effects of IACS-010759 on relapsed/refractory AML and solid tumors are currently under investigation in phase I clinical trials. Another small molecule selectively targeting mitochondrial respiration is BAY 87-2243. Inhibition of mitochondrial complex I by BAY 87-2243 leads to decreased mitochondrial respiration, cellular ATP levels, and thus cell death in melanoma cells. Furthermore, BAY 87-2243 reduced tumor growth in several BRAF-mutant mouse xenografts and patient-derived melanoma mouse models [160] (Table 4). Another new small molecule inhibitor of OXPHOS is Gboxin, which interacts with OXPHOS complexes and thereby seems to inhibit complex V. It decreases growth of glioblastoma cells *in vitro* and *in vivo*. Furthermore, a wide range of cancer cell lines were Gboxin-sensitive whereas non tumor cells were not affected. Only one medulloblastoma cell line and primary mouse malignant peripheral nerve sheath tumor cells were Gboxin resistant. In various glioblastoma models treatment with Gboxin for over one month did not lead to obvious toxicity, making this novel compound a promising candidate for metabolic targeting of a wide range of cancers [161].

## 6. Discussion

The broad variety of tumor entities and plethora of inter-individual differences highlight the importance of identifying therapies able to effectively target pathologies shared by numerous cancer types. Since many solid cancers exhibit the Warburg effect, metabolic therapies potentially could eradicate tumors regardless of their genetic background. Although, numerous studies have shown that drugs which interfere with mitochondrial function can have antitumor effects, it



remains to be demonstrated whether drugs which increase mitochondrial function might also have beneficial effects on tumor therapy. It seems that many cancers have low but functional OXPHOS and are sensitive to changes (up or down) of mitochondrial energy metabolism. Therefore, it is not surprising that fenofibrates initially used for lowering blood lipid levels and known to increase mitochondrial biogenesis show antitumor properties [162,163]. The therapeutic efficacy of inhibitors of mitochondrial energy metabolism might be explained by the fact that tumors frequently have low residual OXPHOS activity that can be further repressed in the tumor cells to deleterious levels by various drugs. However, increasing mitochondrial mass and concomitant OXPHOS activity might influence drug resistance [164]. In addition, it is not clear if respiring tumors or tumors with high metabolic flexibility, as for example subgroups of melanomas, are prone to inhibition of aerobic mitochondrial energy metabolism [15,17,165,166]. A recent study on brain melanoma metastasis indicated that also cancer tissues with a high OXPHOS content can be targeted by OXPHOS inhibitors [159].

Some “old” and “new” drugs might be of special interest because of their widespread use and/or beneficial effects on the overall health of cancer patients. Long-term follow-up studies showed that regular daily Aspirin use reduces the incidence, distant metastasis and mortality of some cancers after approximately 5 years [167–169]. A “new” drug class that might be of special interest for cancer patients are cannabinoids. It is known that they can positively influence mood, appetite and pain [170], three factors which are very important in advanced-stage tumor patients [171]. A limitation of new compounds inhibiting OXPHOS is that their safety still needs to be demonstrated in preclinical but also clinical studies. For example a clinical study with BAY 87-2243 in cancer patients was prematurely terminated due to the occurrence of adverse events (re-occurrence of the adverse event vomiting despite dose reduction and change in formulation of the compound; ClinicalTrials.gov Identifier: NCT01297530).

Regardless of the mode of downregulation of aerobic mitochondrial energy metabolism, complex I seems to be affected in almost all instances. Also, downregulation of mitochondrial biogenesis, replication, transcription and translation, and mtDNA deletion and depletion all can cause reduction of complex I. In addition, the supercomplex organization of the respiratory chain leads to the paradox that most complex III defects also cause secondary loss of complex I assembly and activity [172,173]. NDUFS1, a subunit of mitochondrial complex I can be cleaved by caspase 3. Therefore, complex I can play an important role in apoptosis [174]. The killer lymphocyte protease granzyme A accesses the mitochondrial matrix to cleave NDUFS3, an iron-sulfur subunit of the NADH:ubiquinone oxidoreductase complex I [175]. Natural killer lymphocytes represent the first line of defense against tumor cells [176]. Low levels of complex I and complex I defects seem to confer a growth advantage and anti-apoptotic state on tumor cells; however, total knock down of complex I with the reported drugs seems to be deleterious to tumor cells.

The treatment with OXPHOS inhibitors might not only target cancer cells but also cancer associated cells such as immune cells. For example, T-regulatory cells induce their OXPHOS in an acidic environment and thereby might promote immune tolerance during tissue injury and impair anti-cancer immunity [177]. In this way, cancers can hijack a physiologic mechanism of self-tolerance. Thus, OXPHOS inhibitors might exert their anti-proliferative effects *in vivo* by different mechanisms.

## 7. Conclusion

Inhibition of aerobic mitochondrial energy metabolism represents an attractive therapeutic opportunity against cancer, and repurposing of “old” drugs in tumor therapy holds the potential to effectively kill a broad variety of tumor entities, especially when combined with classic therapeutics.

## Funding

This work was supported by The European Union H2020-MSCA-ITN-2016-722605 (TRANSMIT), Austrian Science Fund (P 31228-B33), the Children's Cancer Foundation Salzburg, Austria and the Vereinigung zur Förderung Pädiatrischer Forschung und Fortbildung Salzburg, Austria.

## Conflict of interest

All authors declare that they have no conflict of interest.

## References

- [1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2019, *CA Cancer J. Clin.* 69 (1) (2019) 7–34.
- [2] L. Fresard, S.B. Montgomery, Diagnosing rare diseases after the exome, *Cold Spring Harb. Mol. Case Stud.* 4 (6) (2018) pii: a003392.
- [3] L.S. Kremer, D.M. Bader, C. Mertes, R. Kopajtic, G. Pichler, A. Iuso, T.B. Haack, E. Graf, T. Schwarzmayr, C. Terrile, E. Konarikova, B. Repp, G. Kastenmuller, J. Adamski, P. Lichtner, C. Leonhardt, B. Funalot, A. Donati, V. Tiranti, A. Lombes, C. Jardel, D. Glaser, R.W. Taylor, D. Ghezzi, J.A. Mayr, A. Rotig, P. Freisinger, F. Distelmaier, T.M. Strom, T. Meitinger, J. Gagneur, H. Prokisch, Genetic diagnosis of Mendelian disorders via RNA sequencing, *Nat. Commun.* 8 (2017) 15824.
- [4] L.S. Kremer, S.B. Wortmann, H. Prokisch, “Transcriptomics”: molecular diagnosis of inborn errors of metabolism via RNA-sequencing, *J. Inher. Metab. Dis.* 41 (3) (2018) 525–532.
- [5] E.A. Ashley, Towards precision medicine, *Nat. Rev. Genet.* 17 (9) (2016) 507–522.
- [6] O. Warburg, Über den Stoffwechsel der Carcinomzelle, *Naturwissenschaften* 50 (1924) 1131–1137.
- [7] O. Warburg, On the origin of cancer cells, *Science* 123 (3191) (1956) 309–314.
- [8] A.A. Shestov, X. Liu, Z. Ser, A.A. Cluntun, Y.P. Hung, L. Huang, D. Kim, A. Le, G. Yellen, J.G. Albeck, J.W. Locasale, Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step, *eLife* 3 (2014).
- [9] R.G. Feichtinger, D. Neureiter, J.A. Mayr, F.A. Zimmermann, F. Berthold, N. Jones, W. Sperl, B. Kofler, Loss of mitochondria in ganglioneuromas, *Front. Biosci. (Elite Ed.)* 3 (2011) 179–186.
- [10] R.G. Feichtinger, F. Zimmermann, J.A. Mayr, D. Neureiter, C. Hauser-Kronberger, F.H. Schilling, N. Jones, W. Sperl, B. Kofler, Low aerobic mitochondrial energy metabolism in poorly- or undifferentiated neuroblastoma, *BMC Cancer* 10 (2010) 149.
- [11] J.A. Mayr, D. Meierhofer, F. Zimmermann, R. Feichtinger, C. Kogler, M. Ratschek, N. Schmeller, W. Sperl, B. Kofler, Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma, *Clin. Cancer Res.* 14 (8) (2008) 2270–2275.
- [12] G. Gasparre, A.M. Porcellini, E. Bonora, L.F. Pennisi, M. Toller, L. Iommarini, A. Ghelli, M. Moretti, C.M. Betts, G.N. Martinelli, A.R. Ceroni, F. Curcio, V. Carelli, M. Rugolo, G. Tallini, G. Romeo, Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncogenic phenotype in thyroid tumors, *Proc. Natl. Acad. Sci. U S A* 104 (21) (2007) 9001–9006.
- [13] D. Astuti, F. Latif, A. Dallol, P.L. Dahia, F. Douglas, E. George, F. Skoldberg, E.S. Husebye, C. Eng, E.R. Maher, Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma, *Am. J. Hum. Genet.* 69 (1) (2001) 49–54.
- [14] R.G. Feichtinger, S. Weis, J.A. Mayr, F. Zimmermann, R. Geilberger, W. Sperl, B. Kofler, Alterations of oxidative phosphorylation complexes in astrocytomas, *Glia* 62 (4) (2014) 514–525.
- [15] R.G. Feichtinger, R. Lang, R. Geilberger, F. Rathje, J.A. Mayr, W. Sperl, J.W. Bauer, C. Hauser-Kronberger, B. Kofler, M. Emberger, Melanoma tumors exhibit a variable but distinct metabolic signature, *Exp. Dermatol.* 27 (2) (2018) 204–207.
- [16] R.G. Feichtinger, D. Neureiter, T. Skaria, S. Wessler, T.L. Cover, J.A. Mayr, F.A. Zimmermann, G. Posselt, W. Sperl, B. Kofler, Oxidative phosphorylation system in gastric carcinomas and gastritis, *Oxid. Med. Cell. Longev.* 2017 (2017) 1320241.
- [17] A. Hall, K.D. Meyle, M.K. Lange, M. Klima, M. Sanderhoff, C. Dahl, C. Abildgaard, K. Thorup, S.M. Moghimi, P.B. Jensen, J. Bartek, P. Guldborg, C. Christensen, Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene, *Oncotarget* 4 (4) (2013) 584–599.
- [18] J. Ho, M.B. de Moura, Y. Lin, G. Vincent, S. Thorne, L.M. Duncan, L. Hui-Min, J.M. Kirkwood, D. Becker, B. Van Houten, S.J. Moschos, Importance of glycolysis and oxidative phosphorylation in advanced melanoma, *Mol. Cancer* 11 (2012) 76.
- [19] K. Polyak, Y. Li, H. Zhu, C. Lengauer, J.K. Willson, S.D. Markowitz, M.A. Trush, K.W. Kinzler, B. Vogelstein, Somatic mutations of the mitochondrial genome in human colorectal tumours, *Nat. Genet.* 20 (3) (1998) 291–293.
- [20] W.Y. Hung, C.W. Wu, P.H. Yin, C.J. Chang, A.F. Li, C.W. Chi, Y.H. Wei, H.C. Lee, Somatic mutations in mitochondrial genome and their potential roles in the progression of human gastric cancer, *Biochim. Biophys. Acta* 1800 (3) (2010) 264–270.
- [21] S.M. Davidson, T. Papagiannakopoulos, B.A. Olenchock, J.E. Heyman, M.A. Keibler, A. Luengo, M.R. Bauer, A.K. Jha, J.P. O'Brien, K.A. Pierce, D.Y. Gui, L.B. Sullivan, T.M. Wasylenko, L. Subbaraj, C.R. Chin, G. Stephanopoulos,

- B.T. Mott, T. Jacks, C.B. Clish, M.G. Vander Heiden, Environment impacts the metabolic dependencies of RAS-driven non-small cell lung cancer, *Cell Metab.* 23 (3) (2016) 517–528.
- [22] Y. Lissanu Deribe, Y. Sun, C. Terranova, F. Khan, J. Martinez-Ledesma, J. Gay, G. Gao, R.A. Mullinax, T. Khor, N. Feng, Y.H. Lin, C.C. Wu, C. Reyes, Q. Peng, F. Robinson, A. Inoue, V. Kochat, C.G. Liu, J.M. Asara, C. Moran, F. Muller, J. Wang, B. Fang, V. Papadimitrakopoulou, I.I. Wistuba, K. Rai, J. Marszalek, P.A. Futreal, Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer, *Nat. Med.* 24 (7) (2018) 1047–1057.
- [23] A. Naguib, G. Mathew, C.R. Reczek, K. Watrud, A. Ambrico, T. Herzka, I.C. Salas, M.F. Lee, N. El-Amine, W. Zheng, M.E. Di Francesco, J.R. Marszalek, D.J. Pappin, N.S. Chandel, L.C. Trotman, Mitochondrial complex I inhibitors expose a vulnerability for selective killing of pten-null cells, *Cell Rep.* 23 (1) (2018) 58–67.
- [24] J. Lee, A.E. Yesilkamal, J.P. Wynne, C. Frankenberger, J. Liu, J. Yan, M. Elbaz, D.C. Rabe, F.D. Rustandy, P. Tiwari, E.A. Grossman, P.C. Hart, C. Kang, S.M. Sanderson, J. Andrade, D.K. Nomura, M.G. Bonini, J.W. Locasale, M.R. Sosner, Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism, *Nature* 568 (7751) (2019) 254–258.
- [25] T. Mashimo, K. Pichumani, V. Vemireddy, K.J. Hatanpaa, D.K. Singh, S. Sirasanagandla, S. Nannepaga, S.G. Piccirillo, Z. Kovacs, C. Foong, Z. Huang, S. Barnett, B.E. Mickey, R.J. DeBerardinis, B.P. Tu, E.A. Maher, R.M. Bachoo, Acetate is a bioenergetic substrate for human glioblastoma and brain metastases, *Cell* 159 (7) (2014) 1603–1614.
- [26] B. Faubert, K.Y. Li, L. Cai, C.T. Hensley, J. Kim, L.G. Zacharias, C. Yang, Q.N. Do, S. Doucette, D. Burguete, H. Li, G. Huet, Q. Yuan, T. Wigal, Y. Butt, M. Ni, J. Torrealba, D. Oliver, R.E. Lenkinski, C.R. Malloy, J.W. Wachsmann, J.D. Young, K. Kernstine, R.J. DeBerardinis, Lactate metabolism in human lung tumors, *Cell* 171 (2) (2017) 358–371 e359.
- [27] S. Hui, J.M. Ghergurovich, R.J. Morscher, C. Jang, X. Teng, W. Lu, L.A. Esparza, T. Reya, Z. Le, J. Yanxiang Guo, E. White, J.D. Rabinowitz, Glucose feeds the TCA cycle via circulating lactate, *Nature* 551 (7678) (2017) 115–118.
- [28] C. Duman, K. Yaqubi, A. Hoffmann, A.A. Acikgoz, A. Korshunov, M. Bendzus, C. Herold-Mende, H.K. Liu, J. Alfonso, Acyl-CoA-Binding protein drives glioblastoma tumorigenesis by sustaining fatty acid oxidation, *Cell Metab.* (2019), <https://doi.org/10.1016/j.cmet.2019.04.004> in press.
- [29] G. Lamonte, X. Tang, J.L. Chen, J. Wu, C.K. Ding, M.M. Keenan, C. Sangokoya, H.N. Kung, O. Ilkayeva, L.G. Boros, C.B. Newgard, J.T. Chi, Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress, *Cancer Metab.* 1 (1) (2013) 23.
- [30] C. Corbet, N. Draoui, F. Polet, A. Pinto, X. Drozak, O. Riant, O. Feron, The SIRT1/HIF2alpha axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy, *Cancer Res.* 74 (19) (2014) 5507–5519.
- [31] N. Draoui, O. Feron, Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments, *Dis. Model. Mech.* 4 (6) (2011) 727–732.
- [32] L. de Bari, A. Atlante, Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming, *Cell Mol. Life Sci.* 75 (15) (2018) 2763–2776.
- [33] T. Sun, N. Zhao, C.S. Ni, X.L. Zhao, W.Z. Zhang, X. Su, D.F. Zhang, Q. Gu, B.C. Sun, Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK), *Cancer Lett.* 285 (2) (2009) 141–150.
- [34] Y. Qin, Q. Zhang, S. Lee, W.L. Zhong, Y.R. Liu, H.J. Liu, D. Zhao, S. Chen, T. Xiao, J. Meng, X.S. Jing, J. Wang, B. Sun, T.T. Dai, C. Yang, T. Sun, H.G. Zhou, Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells, *Oncotarget* 6 (38) (2015) 40667–40679.
- [35] Y. Zhao, X. Wang, L. Li, C. Li, Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and negative cervical cancer cell lines, *Can. J. Physiol. Pharmacol.* 94 (5) (2016) 526–533.
- [36] R. Lamb, M. Fiorillo, A. Chadwick, B. Oszvari, K.J. Reeves, D.L. Smith, R.B. Clarke, S.J. Howell, A.R. Cappello, U.E. Martinez-Outschoorn, M. Peiris-Pages, F. Sotgia, M.P. Lisanti, Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: implications for more effective radiation therapy, *Oncotarget* 6 (16) (2015) 14005–14025.
- [37] W.C. Duivenvoorden, S.V. Popovic, S. Lhotak, E. Seidlitz, H.W. Hirte, R.G. Tozer, G. Singh, Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer, *Cancer Res.* 62 (6) (2002) 1588–1591.
- [38] Z. Lu, N. Xu, B. He, C. Pan, Y. Lan, H. Zhou, X. Liu, Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia, *J. Exp. Clin. Cancer Res.* 36 (1) (2017) 43.
- [39] L. Deng, Y. Lei, R. Liu, J. Li, K. Yuan, Y. Li, Y. Chen, Y. Liu, Y. Lu, C.K. Edwards, 3rd, C. Huang, Y. Wei, Pyrvinium targets autophagy addiction to promote cancer cell death, *Cell Death Dis.* 4 (2013) e614.
- [40] C.J. Hsiao, G. Hsiao, W.L. Chen, S.W. Wang, C.P. Chiang, L.Y. Liu, J.H. Guh, T.H. Lee, C.L. Chung, Cephalochromin induces G0/G1 cell cycle arrest and apoptosis in A549 human non-small-cell lung cancer cells by inflicting mitochondrial disruption, *J. Nat. Prod.* 77 (4) (2014) 758–765.
- [41] B. Wang, J. Ao, D. Yu, T. Rao, Y. Ruan, X. Yao, Inhibition of mitochondrial translation effectively sensitizes renal cell carcinoma to chemotherapy, *Biochem. Biophys. Res. Commun.* 490 (3) (2017) 767–773.
- [42] J. Wang, Y. Xu, H. Wan, J. Hu, Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress, *Biochem. Biophys. Res. Commun.* 497 (1) (2018) 241–247.
- [43] B. Hu, Y. Guo, Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance, *Biochem. Biophys. Res. Commun.* 509 (2) (2019) 373–378.
- [44] Y. Liu, S. Fang, Q. Sun, B. Liu, Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress, *Biochem. Biophys. Res. Commun.* 480 (3) (2016) 415–421.
- [45] W. Xiang, J.K. Cheong, S.H. Ang, B. Teo, P. Xu, K. Asari, W.T. Sun, H. Than, R.M. Bunte, D.M. Virshup, C. Chuah, Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration, *Oncotarget* 6 (32) (2015) 33769–33780.
- [46] Y. Xiong, W. Liu, Q. Huang, J. Wang, Y. Wang, H. Li, X. Fu, Tigecycline as a dual inhibitor of retinoblastoma and angiogenesis via inducing mitochondrial dysfunctions and oxidative damage, *Sci. Rep.* 8 (1) (2018) 11747.
- [47] M. Xiao, L. Zhang, Y. Zhou, P. Rajoria, C. Wang, Pyrvinium selectively induces apoptosis of lymphoma cells through impairing mitochondrial functions and JAK2/STAT5, *Biochem. Biophys. Res. Commun.* 469 (3) (2016) 716–722.
- [48] T.D. Martin, D.R. Cook, M.Y. Choi, M.Z. Li, K.M. Haigis, S.J. Elledge, A role for mitochondrial translation in promotion of viability in K-Ras mutant cells, *Cell Rep.* 20 (2) (2017) 427–438.
- [49] E. Norberg, A. Lako, P.H. Chen, I.A. Stanley, F. Zhou, S.B. Ficarro, B. Chapuy, L. Chen, S. Rodig, D. Shin, D.W. Choi, S. Lee, M.A. Shipp, J.A. Marto, N.N. Danial, Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets, *Cell Death Differ.* 24 (2) (2017) 251–262.
- [50] T. Farge, E. Saland, F. de Toni, N. Aroua, M. Hosseini, R. Perry, C. Bosc, M. Sugita, L. Stuani, M. Fraise, S. Scotland, C. Larue, H. Boutzen, V. Feliu, M.L. Nicolau-Travers, S. Cassant-Sourdy, N. Broin, M. David, N. Serhan, A. Sarry, S. Tavittian, T. Kaoma, L. Vallar, J. Iacovoni, L.K. Linares, C. Montersino, R. Castellano, E. Griesinger, Y. Collette, O. Duchamp, Y. Barreira, P. Hirsch, T. Palama, L. Gales, F. Delhommeau, B.H. Garmy-Susini, J.C. Portais, F. Vergez, M. Selak, G. Danet-Desnoyers, M. Carroll, C. Recher, J.E. Sarry, Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism, *Cancer Discov.* 7 (7) (2017) 716–735.
- [51] E.M. Kuntz, P. Baquero, A.M. Michie, K. Dunn, S. Tardito, T.L. Holyoake, G.V. Helgason, E. Gottlieb, Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells, *Nat. Med.* 23 (10) (2017) 1234–1240.
- [52] X. Fu, W. Liu, Q. Huang, Y. Wang, H. Li, Y. Xiong, Targeting mitochondrial respiration selectively sensitizes pediatric acute lymphoblastic leukemia cell lines and patient samples to standard chemotherapy, *Am. J. Cancer Res.* 7 (12) (2017) 2395–2405.
- [53] S. Kalghatgi, C.S. Spina, J.C. Costello, M. Liesa, J.R. Morones-Ramirez, S. Slomovic, A. Molina, O.S. Shirihai, J.J. Collins, Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells, *Sci. Transl. Med.* 5 (192) (2013) 192ra185.
- [54] M. Fiorillo, R. Lamb, H.B. Tanowitz, A.R. Cappello, U.E. Martinez-Outschoorn, F. Sotgia, M.P. Lisanti, Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potentially blocks the proliferative expansion of stem-like cancer cells (CSCs), *Aging (Albany NY)* 8 (8) (2016) 1593–1607.
- [55] X. Wu, F. Li, X. Wang, C. Li, Q. Meng, C. Wang, J. Huang, S. Chen, Z. Zhu, Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism, *Biochem. Biophys. Res. Commun.* 495 (1) (2018) 267–272.
- [56] F. Tian, C. Wang, M. Tang, J. Li, X. Cheng, S. Zhang, D. Ji, Y. Huang, H. Li, The antibiotic chloramphenicol may be an effective new agent for inhibiting the growth of multiple myeloma, *Oncotarget* 7 (32) (2016) 51934–51942.
- [57] R. Lamb, B. Oszvari, C.L. Lisanti, H.B. Tanowitz, A. Howell, U.E. Martinez-Outschoorn, F. Sotgia, M.P. Lisanti, Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease, *Oncotarget* 6 (7) (2015) 4569–4584.
- [58] Q. Tan, X. Yan, L. Song, H. Yi, P. Li, G. Sun, D. Yu, L. Li, Z. Zeng, Z. Guo, Induction of mitochondrial dysfunction and oxidative damage by antibiotic drug doxycycline enhances the responsiveness of glioblastoma to chemotherapy, *Med. Sci. Monit.* 23 (2017) 4117–4125.
- [59] M. Protasoni, A.M. Kroon, J.W. Taanman, Mitochondria as oncotarget: a comparison between the tetracycline analogs doxycycline and COL-3, *Oncotarget* 9 (73) (2018) 33818–33831.
- [60] M. Skrtic, S. Srisankhadevan, B. Jhas, M. Gebbia, X. Wang, Z. Wang, R. Hurren, Y. Jitkova, M. Gronda, N. Maclean, C.K. Lai, Y. Eberhard, J. Bartoszko, P. Spagnuolo, A.C. Rutledge, A. Datti, T. Ketela, J. Moffat, B.H. Robinson, J.H. Cameron, J. Wrana, C.J. Eaves, M.D. Minden, J.C. Wang, J.E. Dick, K. Humphries, C. Nislow, G. Gjaever, A.D. Schimmer, Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia, *Cancer Cell* 20 (5) (2011) 674–688.
- [61] X. Jia, Z. Gu, W. Chen, J. Jiao, Tigecycline targets non-small cell lung cancer through inhibition of mitochondrial function, *Fundam. Clin. Pharmacol.* 30 (4) (2016) 297–306.
- [62] M. Fiorillo, R. Lamb, H.B. Tanowitz, L. Mutti, M. Krstic-Demonacos, A.R. Cappello, U.E. Martinez-Outschoorn, F. Sotgia, M.P. Lisanti, Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells, *Oncotarget* 7 (23) (2016) 34084–34099.
- [63] M.J. Lee, S.H. Hung, M.C. Huang, T. Tsai, C.T. Chen, Doxycycline potentiates antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy in malignant peripheral nerve sheath tumor cells, *PLoS One* 12 (5) (2017) e0178493.
- [64] M. Zhu, Y. Li, Z. Zhou, Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage, *Biochem. Biophys. Res. Commun.* 492 (3) (2017) 373–378.
- [65] A.L. Luger, B. Sauer, N.I. Lorenz, A.L. Engel, Y. Braun, M. Voss, P.N. Harter, J.P. Steinbach, M.W. Ronellenfitch, Doxycycline impairs mitochondrial function and protects human glioma cells from hypoxia-induced cell death: implications of

- using tet-inducible systems, *Int. J. Mol. Sci.* 19 (5) (2018).
- [66] T.M. Ashton, E. Fokas, L.A. Kunz-Schughart, L.K. Folkes, S. Anbalagan, M. Huether, C.J. Kelly, G. Pirovano, F.M. Buffa, E.M. Hammond, M. Stratford, R.J. Muschel, G.S. Higgins, W.G. McKenna, The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia, *Nat. Commun.* 7 (2016) 12308.
- [67] Y. Harada, I. Ishii, K. Hatake, T. Kasahara, Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3, *Cancer Lett.* 319 (1) (2012) 83–88.
- [68] E. Tomitsuka, K. Kita, H. Esumi, An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system—a unique mitochondrial energy metabolism in tumour microenvironments, *J. Biochem.* 152 (2) (2012) 171–183.
- [69] S.A. Head, W. Shi, L. Zhao, K. Gorshkov, K. Pasunooti, Y. Chen, Z. Deng, R.J. Li, J.S. Shim, W. Tan, T. Hartung, J. Zhang, Y. Zhao, M. Colombini, J.O. Liu, Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells, *Proc. Natl. Acad. Sci. U. S. A.* 112 (52) (2015) E7276–7285.
- [70] T. Arif, Y. Krelin, I. Nakdimon, D. Benharroch, A. Paul, D. Dadon-Klein, V. Shoshan-Barmatz, VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties, *Neuro. Oncol.* 19 (7) (2017) 951–964.
- [71] E.E. McKee, M. Ferguson, A.T. Bentley, T.A. Marks, Inhibition of mammalian mitochondrial protein synthesis by oxazolindiones, *Antimicrob. Agents Chemother.* 50 (6) (2006) 2042–2049.
- [72] C. Scatena, M. Roncella, A. Di Paolo, P. Aretini, M. Menicagli, G. Fanelli, C. Marini, C.M. Mazzanti, M. Ghilli, F. Sotgia, M.P. Lisanti, A.G. Naccarato, Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces cancer stem cells (CSCs) in early breast cancer patients: a clinical pilot study, *Front. Oncol.* 8 (2018) 452.
- [73] B. Oszvari, F. Sotgia, M.P. Lisanti, A new mutation-independent approach to cancer therapy: inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis, *Aging (Albany N.Y.)* 9 (10) (2017) 2098–2116.
- [74] E.M. De Francesco, M. Maggolini, H.B. Tanowitz, F. Sotgia, M.P. Lisanti, Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: implications for optimizing anti-angiogenic therapy, *Oncotarget* 8 (34) (2017) 56126–56142.
- [75] E.M. De Francesco, F. Sotgia, M.P. Lisanti, Cancer stem cells (CSCs): metabolic strategies for their identification and eradication, *Biochem. J.* 475 (9) (2018) 1611–1634.
- [76] P. Sancho, D. Barneda, C. Heeschen, Hallmarks of cancer stem cell metabolism, *Br. J. Cancer* 114 (12) (2016) 1305–1312.
- [77] R. Lamb, H. Harrison, J. Hult, D.L. Smith, M.P. Lisanti, F. Sotgia, Mitochondria as new therapeutic targets for eradicating cancer stem cells: quantitative proteomics and functional validation via MCT1/2 inhibition, *Oncotarget* 5 (22) (2014) 11029–11037.
- [79] B. Boursi, R. Mamtani, K. Haynes, Y.X. Yang, Recurrent antibiotic exposure may promote cancer formation—another step in understanding the role of the human microbiota? *Eur. J. Cancer* 51 (17) (2015) 2655–2664.
- [80] V.K. Dik, M.G. van Oijen, H.M. Smeets, P.D. Siersema, Frequent use of antibiotics is associated with colorectal cancer risk: results of a nested case-control study, *Dig. Dis. Sci.* 61 (1) (2016) 255–264.
- [81] Y. Cao, K. Wu, R. Mehta, D.A. Drew, M. Song, P. Lochhead, L.H. Nguyen, J. Izard, C.S. Fuchs, W.S. Garrett, C. Huttenhower, S. Ogino, E.L. Giovannucci, A.T. Chan, Long-term use of antibiotics and risk of colorectal adenoma, *Gut* 67 (4) (2018) 672–678.
- [82] B. Boursi, K. Haynes, R. Mamtani, Y.X. Yang, Impact of antibiotic exposure on the risk of colorectal cancer, *Pharmacoepidemiol. Drug Saf.* 24 (5) (2015) 534–542.
- [83] I. Ben Sahra, Y. Le Marchand-Brustel, J.F. Tanti, F. Bost, Metformin in cancer therapy: a new perspective for an old antidiabetic drug? *Mol. Cancer Ther.* 9 (5) (2010) 1092–1099.
- [84] A.K. Madiraju, Y. Qiu, R.J. Perry, Y. Rahimi, X.M. Zhang, D. Zhang, J.G. Camporez, G.W. Cline, G.M. Butrico, B.E. Kemp, G. Casals, G.R. Steinberg, D.F. Vatner, K.F. Petersen, G.I. Shulman, Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo, *Nat. Med.* 24 (9) (2018) 1384–1394.
- [85] P. Zabielski, M. Chacinska, K. Charkiewicz, M. Baranowski, J. Gorski, A.U. Blachnio-Zabielska, Effect of metformin on bioactive lipid metabolism in insulin-resistant muscle, *J. Endocrinol.* 233 (3) (2017) 329–340.
- [86] S. Bo, G. Ciccone, R. Rosato, P. Villosio, E. Ghigo, G. Grassi, Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients, *Diabetes Obes. Metab.* 14 (1) (2012) 23–29.
- [87] Y.K. Choi, K.G. Park, Metabolic roles of AMPK and metformin in cancer cells, *Mol. Cells* 36 (4) (2013) 279–287.
- [88] D.M. Abo-Elmatty, E.A. Ahmed, M.K. Tawfik, S.A. Helmy, Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: effect on IGF-1 and tumoral expression of IGF-1 receptors, *Int. Immunopharmacol.* 44 (2017) 72–86.
- [89] H.R. Bridges, A.J. Jones, M.N. Pollak, J. Hirst, Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria, *Biochem. J.* 462 (3) (2014) 475–487.
- [90] M.R. Owen, E. Doran, A.P. Halestrap, Evidence that metformin exerts its anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain, *Biochem. J.* 348 (Pt 3) (2000) 607–614.
- [91] S.M. Fendt, E.L. Bell, M.A. Keibler, S.M. Davidson, G.J. Wirth, B. Fiske, J.R. Mayers, M. Schwab, G. Bellinger, A. Csibi, A. Patnaik, M.J. Blouin, L.C. Cantley, L. Guarente, J. Blenis, M.N. Pollak, A.F. Olumi, M.G. Vander Heiden, G. Stephanopoulos, Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism, *Cancer Res.* 73 (14) (2013) 4429–4438.
- [92] S. Andrzejewski, S.P. Gravel, M. Pollak, J. St-Pierre, Metformin directly acts on mitochondria to alter cellular bioenergetics, *Cancer Metab.* 2 (2014) 12.
- [93] W.W. Wheaton, S.E. Weinberg, R.B. Hamanaka, S. Soberanes, L.B. Sullivan, E. Anso, A. Glasauer, E. Dufour, G.M. Mutlu, G.S. Budigner, N.S. Chandel, Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis, *eLife* 3 (2014) e02242.
- [94] S. Scotland, E. Saland, N. Skuli, F. de Toni, H. Boutzen, E. Micklow, I. Senegas, R. Peyraud, L. Peyriga, F. Theodoro, E. Dumon, Y. Martineau, G. Danet-Desnoyers, F. Bono, C. Rocher, T. Levade, S. Manenti, C. Junot, J.C. Portais, N. Alet, C. Recher, M.A. Selak, M. Carroll, J.E. Sarry, Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells, *Leukemia* 27 (11) (2013) 2129–2138.
- [95] I. Ben Sahra, K. Laurent, S. Giuliano, F. Larbret, G. Ponzio, P. Gounon, Y. Le Marchand-Brustel, S. Giorgetti-Peraldi, M. Cormont, C. Bertolotto, M. Deckert, P. Auberger, J.F. Tanti, F. Bost, Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells, *Cancer Res.* 70 (6) (2010) 2465–2475.
- [96] S. Thakur, B. Daley, K. Gaskins, V.V. Vasko, M. Boufraqueh, D. Patel, C. Sourbier, J. Reece, S.Y. Cheng, E. Kebebew, S. Agarwal, J. Klubo-Gwiezdzinska, Metformin targets mitochondrial glycerophosphate dehydrogenase to control rate of oxidative phosphorylation and growth of thyroid cancer in vitro and in vivo, *Clin. Cancer Res.* 24 (16) (2018) 4030–4043.
- [97] M. Hodeib, M.P. Ogrodzinski, L. Vergnes, K. Reue, B.Y. Karlan, S.Y. Lunt, P.P. Aspuria, Metformin induces distinct bioenergetic and metabolic profiles in sensitive versus resistant high grade serous ovarian cancer and normal fallopian tube secretory epithelial cells, *Oncotarget* 9 (3) (2018) 4044–4060.
- [98] T. Griss, E.E. Vincent, R. Egnatchik, J. Chen, E.H. Ma, B. Faubert, B. Viollet, R.J. DeBerardinis, R.G. Jones, Metformin antagonizes cancer cell proliferation by inhibiting mitochondrial-dependent biosynthesis, *PLoS Biol.* 13 (12) (2015) e1002309.
- [99] D.Y. Gui, L.B. Sullivan, A. Luengo, A.M. Hosios, L.N. Bush, N. Gitego, S.M. Davidson, E. Freinkman, C.J. Thomas, M.G. Vander Heiden, Environment dictates dependence on mitochondrial complex I for NAD<sup>+</sup> and aspartate production and determines cancer cell sensitivity to metformin, *Cell Metab.* 24 (5) (2016) 716–727.
- [100] X. Liu, I.L. Romero, L.M. Litchfield, E. Lengyel, J.W. Locasale, Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers, *Cell Metab.* 24 (5) (2016) 728–739.
- [101] J.H. Cheong, E.S. Park, J. Liang, J.B. Dennison, D. Tsavachidou, C. Nguyen-Charles, K. Wa Cheng, H. Hall, D. Zhang, Y. Lu, M. Ravoori, V. Kundra, J. Ajani, J.S. Lee, W. Ki Hong, G.B. Mills, Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models, *Mol. Cancer Ther.* 10 (12) (2011) 2350–2362.
- [102] S.R. Lord, W.C. Cheng, D. Liu, E. Gaude, S. Haider, T. Metcalf, N. Patel, E.J. Teoh, F. Gleeson, K. Bradley, S. Wigfield, C. Zois, D.R. McGowan, M.L. Ah-See, A.M. Thompson, A. Sharma, L. Bidaut, M. Pollak, P.G. Roy, F. Karpe, T. James, R. English, R.F. Adams, L. Campo, L. Ayers, C. Snell, I. Roxanis, C. Frezza, J.D. Fenwick, F.M. Buffa, A.L. Harris, Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer, *Cell Metab.* 28 (5) (2018) 679–688 e674.
- [103] Z. Zhu, W. Jiang, M.D. Thompson, J.N. McGinley, H.J. Thompson, Metformin as an energy restriction mimetic agent for breast cancer prevention, *J. Carcinog.* 10 (2011) 17.
- [104] J. Velez, R. Pan, J.T. Lee, L. Enciso, M. Suarez, J.E. Duque, D. Jaramillo, C. Lopez, L. Morales, W. Bornmann, M. Konopleva, G. Krystal, M. Andreeff, I. Samudio, Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport, *Oncotarget* 7 (32) (2016) 51435–51449.
- [105] J. Rosand, J.W. Friedberg, J.M. Yang, Fatal phenformin-associated lactic acidosis, *Ann. Intern. Med.* 127 (2) (1997) 170.
- [106] S. de Mey, H. Jiang, C. Corbet, H. Wang, I. Dufait, K. Law, E. Bastien, V. Verovski, T. Gevaert, O. Feron, M. De Ridder, Antidiabetic biguanides radiosensitize hypoxic colorectal cancer cells through a decrease in oxygen consumption, *Front. Pharmacol.* 9 (2018) 1073.
- [107] K. Birsoy, R. Possemato, F.K. Lorbeer, E.C. Bayraktar, P. Thiru, B. Yucel, T. Wang, W.W. Chen, C.B. Clish, D.M. Sabatini, Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides, *Nature* 508 (7494) (2014) 108–112.
- [108] W.K. Miskimins, H.J. Ahn, J.Y. Kim, S. Ryu, Y.S. Jung, J.Y. Choi, Synergistic anti-cancer effect of phenformin and oxamate, *PLoS One* 9 (1) (2014) e85576.
- [109] L.A. Villani, B.K. Smith, K. Marcinko, R.J. Ford, L.A. Broadfield, A.E. Green, V.P. Houde, P. Muti, T. Tsakiridis, G.R. Steinberg, The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration, *Mol. Metab.* 5 (10) (2016) 1048–1056.
- [110] E. Gottfried, S. Rogenhofer, H. Waibel, L.A. Kunz-Schughart, A. Reichle, M. Wehrstein, A. Peuker, K. Peter, G. Hartmannsgruber, R. Andreesen, M. Kreutz, Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids, *Cancer Chemother. Pharmacol.* 67 (1) (2011) 117–126.
- [111] J.B. Custodio, C.M. Cardoso, M.S. Santos, L.M. Almeida, J.A. Vicente, M.A. Fernandes, Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents, *Toxicology* 259 (1–2) (2009) 18–24.
- [112] S. Trumbeckaite, V. Cesna, A. Jasukaitiene, R. Baniene, A. Gulbina, Different mitochondrial response to cisplatin and hyperthermia treatment in human AGS, Caco-2 and T3M4 cancer cell lines, *J. Bioenerg. Biomembr.* 50 (5) (2018) 329–338.
- [113] B. Ortega-Dominguez, O.E. Aparicio-Trejo, F.E. Garcia-Arroyo, J.C. Leon-Contreras, E. Tapia, E. Molina-Jijon, R. Hernandez-Pando, L.G. Sanchez-Lozada,



- D. Barrera-Oviedo, J. Pedraza-Chaverri, Curcumin prevents cisplatin-induced renal alterations in mitochondrial bioenergetics and dynamic, *Food Chem. Toxicol.* 107 (Pt A) (2017) 373–385.
- [114] T. Cunha-Oliveira, L.L. Ferreira, A.R. Coelho, C.M. Deus, P.J. Oliveira, Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes, *Toxicol. Appl. Pharmacol.* 348 (2018) 1–13.
- [115] L.L. Ferreira, T. Cunha-Oliveira, C.D. Veloso, C.F. Costa, K.B. Wallace, P.J. Oliveira, Single nanomolar doxorubicin exposure triggers compensatory mitochondrial responses in H9c2 cardiomyoblasts, *Food Chem. Toxicol.* 124 (2019) 450–461.
- [116] B. Aryal, V.A. Rao, Deficiency in Cardiolipin reduces doxorubicin-induced oxidative stress and mitochondrial damage in human B-Lymphocytes, *PLoS One* 11 (7) (2016) e0158376.
- [117] S.E. Lipshultz, L.M. Anderson, T.L. Miller, M. Gerschenson, K.E. Stevenson, D.S. Neuberg, V.I. Franco, D.E. LiButti, L.B. Silverman, L.M. Vrooman, S.E. Sallan, C. Dana-Farber, Cancer Institute Acute Lymphoblastic Leukemia, Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors, *Cancer* 122 (6) (2016) 946–953.
- [118] K.B. Wallace, Doxorubicin-induced cardiac mitochondriopathy, *Pharmacol. Toxicol.* 93 (3) (2003) 105–115.
- [119] N. Yadav, S. Kumar, T. Marlowe, A.K. Chaudhary, R. Kumar, J. Wang, J. O'Malley, P.M. Boland, S. Jayanthi, T.K. Kumar, N. Yadava, D. Chandra, Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents, *Cell Death Dis.* 6 (2015) e1969.
- [120] V. Tesori, A.C. Piscaglia, D. Samengo, M. Barba, C. Bernardini, R. Scatena, A. Pontoglio, L. Castellini, J.N. Spelbrink, G. Maulucci, M.A. Puglisi, G. Pani, A. Gasbarrini, The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing, *Sci. Rep.* 5 (2015) 9149.
- [121] V.H. Bull, K. Rajalingam, B. Thiede, Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells, *J. Proteome Res.* 11 (3) (2012) 1609–1620.
- [122] K. Okada, Y. Nakano, K. Yamasaki, C. Nitani, H. Fujisaki, J. Hara, Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases, *Cancer Med.* 5 (8) (2016) 1947–1949.
- [123] A. Kallio, A. Zheng, J. Dahllund, K.M. Heiskanen, P. Harkonen, Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells, *Apoptosis* 10 (6) (2005) 1395–1410.
- [124] C.M. Cardoso, J.B. Custodio, L.M. Almeida, A.J. Moreno, Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency, *Toxicol. Appl. Pharmacol.* 176 (3) (2001) 145–152.
- [125] P.I. Moreira, J. Custodio, A. Moreno, C.R. Oliveira, M.S. Santos, Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure, *J. Biol. Chem.* 281 (15) (2006) 10143–10152.
- [126] I. Larosche, P. Letteron, B. Fromenty, N. Vadrot, A. Abbey-Toby, G. Feldmann, D. Pessayre, A. Mansouri, Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver, *J. Pharmacol. Exp. Ther.* 321 (2) (2007) 526–535.
- [127] P. Sansone, C. Ceccarelli, M. Berishaj, Q. Chang, V.K. Rajasekhar, F. Perna, R.L. Bowman, M. Vidone, L. Daly, J. Nnoli, D. Santini, M. Taffurelli, N.N. Shih, M. Feldman, J.J. Mao, C. Colameco, J. Chen, A. DeMichele, N. Fabbri, J.H. Healey, M. Ricca, G. Gasparre, D. Lyden, M. Bonafe, J. Bromberg, Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer, *Nat. Commun.* 7 (2016) 10442.
- [128] K. Rohlenova, K. Sachaphibulkij, J. Stursa, A. Bezawork-Geleta, J. Blecha, B. Endaya, L. Werner, J. Cerny, R. Zobalova, J. Goodwin, T. Spacek, E. Alizadeh Pesar, B. Yan, M.N. Nguyen, M. Vondrusova, M. Sobol, P. Jezek, P. Hozak, J. Truksa, J. Rohlena, L.F. Dong, J. Neuzil, Selective disruption of respiratory supercomplexes as a new strategy to suppress Her2(high) breast Cancer, *Antioxid. Redox Signal.* 26 (2) (2017) 84–103.
- [129] S. Hubackova, E. Davidova, K. Rohlenova, J. Stursa, L. Werner, L. Andera, L. Dong, M.G. Terp, Z. Hodny, H.J. Ditzel, J. Rohlena, J. Neuzil, Selective elimination of senescent cells by mitochondrial targeting is regulated by AN2, *Cell Death Differ.* 26 (2) (2019) 276–290.
- [130] B.T. Paul, D.H. Manz, F.M. Torti, S.V. Torti, Mitochondria and Iron: current questions, *Expert Rev. Hematol.* 10 (1) (2017) 65–79.
- [131] R.V. Simoes, S. Veeraperumal, I.S. Serganova, N. Kruchevsky, J. Varshavsky, R.G. Blasberg, E. Ackerstaff, J.A. Koutcher, Inhibition of prostate cancer proliferation by Deferiprone, *NMR Biomed.* 30 (6) (2017).
- [132] X. Zhang, M. Fryknas, E. Hernlund, W. Fayad, A. De Milito, M.H. Olofsson, V. Gogvadze, L. Dang, S. Pahlman, L.A. Schughart, L. Rickardson, P. D'Arcy, J. Gullbo, P. Nygren, R. Larsson, S. Linder, Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised micro-environments, *Nat. Commun.* 5 (2014) 3295.
- [133] M. Fryknas, X. Zhang, U. Bremberg, V. Senkowski, M.H. Olofsson, P. Brandt, I. Persson, P. D'Arcy, J. Gullbo, P. Nygren, L.K. Schughart, S. Linder, R. Larsson, Iron chelators target both proliferating and quiescent cancer cells, *Sci. Rep.* 6 (2016) 38343.
- [134] G.A. Vitiello, B.D. Medina, S. Zeng, T.G. Bowler, J.Q. Zhang, J.K. Loo, N.J. Param, M. Liu, A.J. Moral, J.N. Zhao, F. Rossi, C.R. Antonescu, V.P. Balachandran, J.R. Cross, R.P. DeMatteo, Mitochondrial inhibition augments the efficacy of Imatinib by resetting the metabolic phenotype of gastrointestinal stromal tumor, *Clin. Cancer Res.* 24 (4) (2018) 972–984.
- [135] K. Mody, A.S. Mansfield, L. Vemireddy, P. Nygren, J. Gulbo, M. Borad, A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors, *Invest. New Drugs* (2018), <https://doi.org/10.1007/s10637-018-0703-9>.
- [136] K.K. Kim, S. Abelman, N. Yano, J.R. Ribeiro, R.K. Singh, M. Tipping, R.G. Moore, Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1alpha in cancer cells, *Sci. Rep.* 5 (2015) 14296.
- [137] S. Ishida, P. Andreux, C. Poitry-Yamate, J. Auwerx, D. Hanahan, Bioavailable copper modulates oxidative phosphorylation and growth of tumors, *Proc. Natl. Acad. Sci. U. S. A.* 110 (48) (2013) 19507–19512.
- [138] M.F. Lombardo, M.R. Ciriolo, G. Rotilio, L. Rossi, Prolonged copper depletion induces expression of antioxidants and triggers apoptosis in SH-SY5Y neuroblastoma cells, *Cell Mol. Life Sci.* 60 (8) (2003) 1733–1743.
- [139] J. Navratilova, M. Karasova, M. Kohutkova Lanova, L. Jirakova, Z. Budkova, J. Pachernik, J. Smarda, P. Benes, Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate, *J. Cell. Mol. Med.* 21 (9) (2017) 1859–1869.
- [140] B. Pasche, M. Wang, M. Pennison, H. Jimenez, Prevention and treatment of cancer with aspirin: where do we stand? *Semin. Oncol.* 41 (3) (2014) 397–401.
- [141] J.R. Vane, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, *Nat. New Biol.* 231 (25) (1971) 232–235.
- [142] K.C. Zimmermann, N.J. Waterhouse, J.C. Goldstein, M. Schuler, D.R. Green, Aspirin induces apoptosis through release of cytochrome c from mitochondria, *Neoplasia* 2 (6) (2000) 505–513.
- [143] P. Maity, S. Bindu, S. Dey, M. Goyal, A. Alam, C. Pal, K. Mitra, U. Bandyopadhyay, Indomethacin, a non-steroidal anti-inflammatory drug, develops gastropathy by inducing reactive oxygen species-mediated mitochondrial pathology and associated apoptosis in gastric mucosa: a novel role of mitochondrial aconitase oxidation, *J. Biol. Chem.* 284 (5) (2009) 3058–3068.
- [144] C. Carrasco-Pozo, M. Gotteland, H. Speisky, Protection by apple peel polyphenols against indomethacin-induced oxidative stress, mitochondrial damage and cytotoxicity in Caco-2 cells, *J. Pharm. Pharmacol.* 62 (7) (2010) 943–950.
- [145] C. Sandoval-Acuna, C. Lopez-Alarcon, M.E. Aliaga, H. Speisky, Inhibition of mitochondrial complex I by various non-steroidal anti-inflammatory drugs and its protection by quercetin via a coenzyme Q-like action, *Chem. Biol. Interact.* 199 (1) (2012) 18–28.
- [146] C. Carrasco-Pozo, M. Gotteland, H. Speisky, Apple peel polyphenol extract protects against indomethacin-induced damage in Caco-2 cells by preventing mitochondrial complex I inhibition, *J. Agric. Food Chem.* 59 (21) (2011) 11501–11508.
- [147] H. Raza, A. John, S. Benedict, Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells, *Eur. J. Pharmacol.* 668 (1–2) (2011) 15–24.
- [148] C. Brummer, S. Faerber, C. Bruss, C. Blank, R. Lacroix, S. Haferkamp, W. Herr, M. Kreuz, K. Renner, Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma, *Cancer Lett.* 442 (2019) 453–463.
- [149] R. Ramer, B. Hinz, Cannabinoids as anticancer drugs, *Adv. Pharmacol.* 80 (2017) 397–436.
- [150] B. Hinz, R. Ramer, Anti-tumour actions of cannabinoids, *Br. J. Pharmacol.* 176 (10) (2019) 1384–1394.
- [151] A. Athanasiou, A.B. Clarke, A.E. Turner, N.M. Kumaran, S. Vakilpour, P.A. Smith, D. Bagiokou, T.D. Bradshaw, A.D. Westwell, L. Fang, D.N. Lobo, C.S. Constantinescu, V. Calabrese, A. Loesch, S.P. Alexander, R.H. Clothier, D.A. Kendall, T.E. Bates, Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death, *Biochem. Biophys. Res. Commun.* 364 (1) (2007) 131–137.
- [152] J.M. Mahoney, R.A. Harris, Effect of Δ9-tetrahydrocannabinol on mitochondrial processes, *Biochem. Pharmacol.* 21 (9) (1972) 1217–1226.
- [153] S.D. McAllister, R. Murase, R.T. Christian, D. Lau, A.J. Zielinski, J. Allison, C. Almanza, A. Pakdel, J. Lee, C. Limbad, Y. Liu, R.J. Debs, D.H. Moore, P.Y. Desprez, Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis, *Breast Cancer Res. Treat.* 129 (1) (2011) 37–47.
- [154] D.A. Whyte, S. Al-Hammadi, G. Balhaj, O.M. Brown, H.S. Penefsky, A.K. Souid, Cannabinoids inhibit cellular respiration of human oral cancer cells, *Pharmacology* 85 (6) (2010) 328–335.
- [155] C. Moren, D.L. Juarez-Flores, F. Cardellach, G. Garrabou, The role of therapeutic drugs on acquired mitochondrial toxicity, *Curr. Drug Metab.* 17 (7) (2016) 648–662.
- [156] T. Komulainen, T. Lodge, R. Hinttala, M. Buzsak, M. Pietila, P. Koivunen, J. Hakkola, J. Poulton, K.J. Morten, J. Uusimaa, Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model, *Toxicology* 331 (2015) 47–56.
- [157] S.C. Higgins, G.J. Pilkington, The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma, *Anticancer Res.* 30 (2) (2010) 391–397.
- [158] J.R. Molina, Y. Sun, M. Protopopova, S. Gera, M. Bandi, C. Bristow, T. McAfoos, P. Morlacchi, J. Ackroyd, A.A. Agip, G. Al-Atrash, J. Asara, J. Bardenhagen, C.C. Carrillo, C. Carroll, E. Chang, S. Ciurea, J.B. Cross, B. Czako, A. Deem, N. Daver, J.F. de Groot, J.W. Dong, N. Feng, G. Gao, J. Gay, M.G. Do, J. Greer, V. Giuliani, J. Han, L. Han, V.K. Henry, J. Hirst, S. Huang, Y. Jiang, Z. Kang, T. Khor, S. Konoplev, Y.H. Lin, G. Liu, A. Lodi, T. Lofton, H. Ma, M. Mahendra, P. Matre, R. Mullinax, M. Peoples, A. Petrocchi, J. Rodriguez-Canale, R. Serreli, T. Shi, M. Smith, Y. Tabe, J. Therooff, S. Tiziani, Q. Xu, Q. Zhang, F. Muller, R.A. DePinho, C. Toniatti, G.F. Draetta, T.P. Heffernan, M. Konopleva, P. Jones, M.E. Di Francesco, J.R. Marszalek, An inhibitor of oxidative phosphorylation exploits cancer vulnerability, *Nat. Med.* 24 (7) (2018) 1036–1046.
- [159] G.M. Fischer, A. Jalali, D.A. Kircher, W.C. Lee, J.L. McQuade, L.E. Hayday, A.Y. Joon, A. Reuben, M.P. de Macedo, F.C.L. Carapeto, C. Yang, A. Srivastava, C.R. Ambati, A. Sreekumar, C.W. Hudgens, B. Knighton, W. Deng, S.D. Ferguson,

- H.A. Tawbi, I.C. Glitza, J.E. Gershenwald, Y.N. Vashisht Gopal, P. Hwu, J.T. Huse, J.A. Wargo, P.A. Futreal, N. Putluri, A.J. Lazar, R.J. DeBerardinis, J.R. Marszalek, J. Zhang, S.L. Holmen, M.T. Tetzlaff, M.A. Davies, Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases, *Cancer Discov.* 9 (5) (2019) 628–645.
- [160] L. Schockel, A. Glasauer, F. Basit, K. Bitschar, H. Truong, G. Erdmann, C. Algire, A. Hagebarth, P.H. Willems, C. Kopitz, W.J. Koopman, M. Heroult, Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth, *Cancer Metab.* 3 (2015) 11.
- [161] Y. Shi, S.K. Lim, Q. Liang, S.V. Iyer, H.Y. Wang, Z. Wang, X. Xie, D. Sun, Y.J. Chen, V. Tabar, P. Gutin, N. Williams, J.K. De Brabander, L.F. Parada, Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma, *Nature* 567 (7748) (2019) 341–346.
- [162] X. Lian, G. Wang, H. Zhou, Z. Zheng, Y. Fu, L. Cai, Anticancer properties of fenofibrate: a repurposing use, *J. Cancer* 9 (9) (2018) 1527–1537.
- [163] X. Wang, C.T. Moraes, Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels, *Mol. Oncol.* 5 (5) (2011) 399–409.
- [164] F. Guerra, A.A. Arbini, L. Moro, Mitochondria and cancer chemoresistance, *Biochim. Biophys. Acta. Bioenerg.* 1858 (8) (2017) 686–699.
- [165] M.F. Rodrigues, E. Obre, F.H. de Melo, G.C. Santos Jr, A. Galina, M.G. Jasiulionis, R. Rossignol, F.D. Rumjanek, N.D. Amoedo, Enhanced OXPHOS, glutaminolysis and beta-oxidation constitute the metastatic phenotype of melanoma cells, *Biochem. J.* 473 (6) (2016) 703–715.
- [166] A. Ferretta, I. Maida, S. Guida, A. Azzariti, L. Porcelli, S. Tommasi, P. Zanna, T. Cocco, M. Guida, G. Guida, New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations, *Biochim. Biophys. Acta* 1863 (11) (2016) 2710–2718.
- [167] P.M. Rothwell, M. Wilson, C.E. Elwin, B. Norrving, A. Algra, C.P. Warlow, T.W. Meade, Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, *Lancet* 376 (9754) (2010) 1741–1750.
- [168] P.M. Rothwell, F.G. Fowkes, J.F. Belch, H. Ogawa, C.P. Warlow, T.W. Meade, Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials, *Lancet* 377 (9759) (2011) 31–41.
- [169] P.M. Rothwell, M. Wilson, J.F. Price, J.F. Belch, T.W. Meade, Z. Mehta, Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials, *Lancet* 379 (9826) (2012) 1591–1601.
- [170] D.I. Abrams, M. Guzman, Cannabis in cancer care, *Clin. Pharmacol. Ther.* 97 (6) (2015) 575–586.
- [171] J.L. Kramer, Medical marijuana for cancer, *CA Cancer J. Clin.* 65 (2) (2015) 109–122.
- [172] J.A. Letts, L.A. Sazanov, Clarifying the supercomplex: the higher-order organization of the mitochondrial electron transport chain, *Nat. Struct. Mol. Biol.* 24 (10) (2017) 800–808.
- [173] R.G. Feichtinger, M. Brunner-Krainz, B. Alhaddad, S.B. Wortmann, R. Kovacs-Nagy, T. Stojakovic, W. Erwa, B. Resch, W. Windischhofer, S. Verheyen, S. Uhrig, C. Windpassinger, F. Locker, C. Makowski, T.M. Strom, T. Meitinger, H. Prokisch, W. Sperl, T.B. Haack, J.A. Mayr, Combined respiratory chain deficiency and UQC2 mutations in neonatal encephalomyopathy: defective supercomplex assembly in complex III deficiencies, *Oxid. Med. Cell. Longev.* 2017 (2017) 7202589.
- [174] J.E. Ricci, C. Munoz-Pinedo, P. Fitzgerald, B. Bailly-Maitre, G.A. Perkins, N. Yadava, I.E. Scheffler, M.H. Ellisman, D.R. Green, Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain, *Cell* 117 (6) (2004) 773–786.
- [175] D. Martinvalet, D.M. Dykxhoorn, R. Ferrini, J. Lieberman, Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death, *Cell* 133 (4) (2008) 681–692.
- [176] M. Papamichail, S.A. Perez, A.D. Gritzapis, C.N. Baxevanis, Natural killer lymphocytes: biology, development, and function, *Cancer Immunol. Immunother.* 53 (3) (2004) 176–186.
- [177] A. Angelin, L. Gil-de-Gomez, S. Dahiya, J. Jiao, L. Guo, M.H. Levine, Z. Wang, W.J. Quinn 3rd, P.K. Kopinski, L. Wang, T. Akimova, Y. Liu, T.R. Bhatti, R. Han, B.L. Laskin, J.A. Baur, I.A. Blair, D.C. Wallace, W.W. Hancock, U.H. Beier, Foxp3 reprograms t cell metabolism to function in Low-Glucose, high-lactate environments, *Cell Metab.* 25 (6) (2017) 1282–1293 e1287.
- [178] R. Kikuchi, Y. Iwai, T. Tsuji, Y. Watanabe, N. Koyama, K. Yamaguchi, H. Nakamura, K. Aoshiba, Hypercapnic tumor microenvironment confers chemoresistance to lung cancer cells by reprogramming mitochondrial metabolism in vitro, *Free Radic. Biol. Med.* 134 (2019) 200–221.
- [179] L. Ippolito, A. Morandi, M.L. Taddei, M. Parri, G. Comito, A. Iscaro, M.R. Raspollini, F. Magherini, E. Rapizzi, J. Masquelier, G.G. Muccioli, P. Sonveaux, P. Chiarugi, E. Giannoni, Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer, *Oncogene* (2019), <https://doi.org/10.1038/s41388-019-0805-7>.